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ABSTRACT 
Background: Economic evaluations are increasingly being used to inform decision makers 
regarding the allocation of scarce health care resources. In reimbursement applications to the 
Norwegian Drug Reimbursement Scheme the cost-utility analysis (CUA) is a common feature, 
expressing the cost-effectiveness of a treatment. Norwegian Medicines Agency (NoMA), 
which administers the scheme, is interested in supplementing the existing dossier with 
measurements of the conditions severity level. During their work on revising the 
pharmacoeconomic guidelines they identified a lack of empirical studies concerning severity 
measures (NoMA, 2011b). 
Objective: To find out how to operationalize severity measurements in a Norwegian context 
and investigate the implications of the included severity measures; providing a contribution to 
the discussion of severity level in Norway. 
Method: An explorative approach with a systematic literature review to identify different 
severity measures. Quality-adjusted life expectancy (QALE) based on Scandinavian data is 
developed to establish a reference class for the included conditions. The data material is 
reimbursement applications received by NoMA in the period 2009-2011, including 20 cases in 
the analysis.  
Results: Two severity measures, Absolute shortfall (AS) and Proportional shortfall (PS), are 
included and operationalized. They both make use of Quality-adjusted lifeyar (QALY) utility 
values, but have a fundamental difference in how the age of the patient is handled. None of 
them stands out as being clearly superior regarding existing policy and studies concerning the 
public opinion. 
Conclusions: NoMA and other governmental agencies could get useful information to utilize in 
resource allocation if doing a more consistent evaluation of medical conditions’ severity levels. 
AS favored younger individuals, but the age component was reduced by including discounting 
in the procedure. PS was more sensitive to conditions with an expected death in near future 
independent of patient’s age. The thesis identifies various components that have to be 
addressed to developers of pharmacoeconomic models to achieve valid measurements. This 
type of methodology are not widespread and it would be interesting to see more research done 
on applying severity measures to real-life data to develop new and refine existing principles. 
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1. INTRODUCTION 
Economic evaluations are increasingly being used to inform decision makers regarding the 
allocation of scarce health care resources. The aim of pharmacoeconomics is to compare the 
value of one drug or therapy against another when both costs and effect are taken into 
consideration. These kinds of studies serve to guide an optimal allocation of healthcare 
resources, in a standardized and scientifically grounded manner. In the reimbursement 
applications to the Norwegian Drug Reimbursement Scheme (Blåreseptordningen) the cost-
utility analysis (CUA) is a common feature, usually expressing the benefits of a drug in 
quality-adjusted-life-year (QALY). Politicians and other decision makers might want to 
valuate different aspects of health when distributing health care resources and a recurring 
issue is the consideration of the severity of a condition. In Norwegian healthcare policy, a 
condition’s level of severity is one of three core values that are considered when assigning 
priority; in addition to the efficacy and cost-effectiveness of the intervention (Morland et al., 
2010, MoH, 2001).  
How should we measure and quantify the severity of a medical condition? Variables as risk of 
death, loss of physical and physiological functionality, pain, discomfort, and former 
experienced health are all affecting how people would characterize the level of severity. There 
exist various methods and principles of measuring a condition’s severity within and between 
medical areas. At Norwegian policy level, there are no accepted standards in how this 
measurement should be operationalized and consequently governmental bodies as the 
Norwegian Medicines Agency (NoMA), are using an arbitrary approach.  
NoMA acknowledges this shortcoming and experienced a lack of empirical studies in how to 
operationalize the level of severity when they recently revised the pharmacoeconomic 
guidelines for the Drug Reimbursement Scheme (NoMA, 2011b). Among the efforts to gain 
more knowledge about the topic, NoMA made a master thesis proposal that this paper is 
responding to. By using data from previous reimbursement applications, NoMA wants more 
knowledge about implications of severity measures and how different disease areas are 
evaluated. This thesis will investigate different approaches in how to improve the 
shortcomings that exists, and examine different factors that enables or complicates the 
implementation of measurement methods. 
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The research question that is examined in this thesis is: 
How can severity measurements be operationalized in applications to the Norwegian Drug 
Reimbursement Scheme, and what are the implications of alternative measures? 
The investigation of the research question is carried out with an explorative approach with a 
desire to give an empirical contribution to the ongoing debate concerning severity measures. 
1.1 Thesis structure 
Chapter 1 is the introduction to the thesis and a brief explanation of two central concepts of 
the thesis. Chapter 2 introduces the institutional context of the research question and tries to 
define some of the existing Norwegian policy concerning severity level in health economic 
analysis. Chapter 3 gives a theoretical background presenting philosophical and 
methodological approaches to the severity issue. Chapter 4 outlines the study design, the 
search strategy used to identify relevant severity measures and the data material. This chapter 
takes also a deeper tour into the specific severity principles and the empirical model 
developed for the analysis. To get a more comprehensive understanding of the data material, a 
brief introduction is given to the different conditions included. The results of the analysis is 
presented in chapter 5. In chapter 6, the findings of the analyses are discussed emphasizing 
the issues of operationalization and implications of severity measures in pharmacoeconomic 
analyses. Since the thesis also serves an exploring purpose to the topic, attention are given to 
the requirements and challenges to achieve measurements of validity. Chapter 7 concludes 
this study and gives suggestions for future research.  
1.2 QALY and QALE 
Quality-adjusted life year (QALY) have increasingly been used in the assessment of health 
interventions for the last three decades. QALY is a measure that combines health related 
quality of life (HRQL) (h) on a scale of 0 to 1, with a time dimension (t), and are expressed 
with the following equation: 
(1) 	
 = ℎ ×  
It is assumed that a year of life lived in a state of less than perfect health is worth less than 1, 
e.g. 0.8 (h) × 1 (t) = 0.8 QALYs. QALY are often used in cost-utility analyses (CUA) to 
calculate the ratio of costs to QALYs gained for a particular healthcare intervention. An 
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advantage of this method is that it makes possible doing comparisons between different 
interventions for various diseases and conditions (Drummond et al., 2005, Sassi, 2006).  
A related principle to QALY is the Quality Adjusted Life Expectancy (QALE), which is the 
number of years of perfect health one can expect to live from a certain age, and it is a 
summary measure of mortality and HRQL across different stages of life. QALE as a measure 
summarizes the overall health for the population and provides comparisons among different 
groups (Jia et al., 2012). The concepts and the underlying factors are being discussed 
throughout the thesis.  
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2 INSTITUTIONAL FRAMEWORK 
2.1 Norwegian drug reimbursement scheme 
The Norwegian Medicines Agency (NoMA) is responsible for preparing recommendations 
and when relevant passes resolutions concerning acceptance of drugs to the reimbursement 
scheme (Blåreseptordningen). NoMA assesses annually approximately 110 reimbursement 
cases that include applications for reimbursement of generic drugs, new administration 
methods, new strength, new active substances and new indications for existing substances. 
The applications must include a pharmacoeconomic analysis of the drug according to the 
Guidelines for Pharmacoeconomic Evaluations (NoMA, 2012b). Based on reimbursement 
applications submitted, as well as NoMAs own reports; health outcomes, cost effectiveness, 
and the overall budget impacts are evaluated. The perspective in the cost effectiveness 
analysis is a societal, with some limitations. NoMA will come to a decision on its own, or 
make a recommendation to the Ministry of Health and Care Services (abbreviated: MoH). 
MoH assesses applications that have an estimated net budget impact for the National 
Insurance’ pharmaceutical budget (Folketrygden) of more than five million NOK in the fifth 
year of reimbursement. In these cases the reimbursement decision is taken by the Storting 
(The Parliament) after a proposal from the Ministry (MoH, 2012, NoMA, 2005) 
Comprehensive reimbursement applications include a cost-utility analysis (CUA). The 
advantage of this well-established method is that is makes it possible to compare the value of 
funding for entirely different competing programs. Research indicates that priority setting 
between programs according to cost per QALY methods in many cases does not correspond 
well with the societal preference of what is fair and ethical (Nord, 1993a, Ubel, 1999). The 
QALY approach is based on an idea to maximize health production, but a society such as the 
Norwegian, also seeks to prioritize according to degree of severity (where effective treatment 
does exist) (NoMA, 2005, NOU, 1997). A drug can be accepted for reimbursement if the 
criteria stated in § 14–13 in the medicine regulation are fulfilled: 
a) treatment or prevention of a severe condition 
b) long-lasting condition 
c) clinical effectiveness (efficacy) 
d) cost-effective 
(NoMA, 2011a) 
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2.2 Guidelines and norms concerning severity in the Norwegian 
health-sector   
Two reports from the Lønning Commissions have provided terms of concepts for 
development of health care policy in Norway, leading for instance to the Regulations on the 
Prioritization of Health Services and the Right to Health Care and the Patient Rights Act of 
2001 (MoH, 2001, NOU, 1997). One of the important elements of this work is the 
recommendation that priority should be given according to three criteria: 
- Severity of the condition 
- The expected outcome from the intervention 
- A reasonable cost-effectiveness ratio 
The commission has defined that severity could be an expression of lost lifetime and quality 
of life compared to the average population, if treatment is not initiated. According to the 
commission’s opinion a condition could be determined to be severe based on an assessment 
of: 
- Death risk or loss of functionality 
- The extent of physical and physiological loss of functionality 
- Pain, physical or physiological discomfort (e.g. short-windedness, dizziness, anxiety) 
The commission has not been more specific, and operationalizing of the topic is therefore 
open to interpretation for both governmental agencies, different organizations and the patients 
themselves. To establish a goal of equal health state for everyone is characterized as 
unrealistic. However, conditions that deviates the most from normal health should be given 
the highest priority. The severity level of a condition itself does not indicate a high priority if 
the patient group only can expect a marginal or no outcome of the treatment (NOU, 1997) 
It is a common comprehension that young people’s health is a precious resource in a society, 
and some would claim that this is an integrated concern in what people understand as a severe 
condition. How the age of the patient should influence a measure of severity is not determined 
by the policymakers. The age dimension is not emphasized in the severity definitions from the 
Lønning Commission, but the Guidelines for Priority Setting is stating that a reduction of life 
expectancy is relevant for the right to receive necessary healthcare (MoH, 2001).  
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3 THEORETICAL FRAMEWORK 
There are different ways to approach the severity concept. In this chapter, I will present 
different theories, statements and principles concerning severity. 
3.1 Health, disease and severity  
As a fundamental approach to severity, Christopher Boorse’s influential (1977) definition of 
health and disease as theoretical concepts is chosen: 
1. The reference class is a natural class of organisms of uniform functional design; 
specifically, an age group of sex of a species. 
2. A normal function of a part of process within members of a reference class is a 
statistically typical contribution by it to their individual survival and reproduction. 
3. A disease is a type of internal state that is tither an impairment of normal functional 
ability, i.e. a reduction of one or more functional ability, i.e. a reduction of one or 
more functional abilities below typical efficiency, or a limitation on functional ability 
caused by environmental agents. 
4. Health is the absence of disease (Boorse, 1977) 
The magnitude of deviation from what are expected as health could therefore be a definition 
of the level of severity of a condition. This also seems to be in accordance with the more 
specified definitions from the Lønning Commission (NOU, 1997) and the two approaches 
serves as a theoretical basis in this thesis. 
3.2 Severity 
To be able to have a distinct approach to the topic it is of importance to be able to refine the 
concept and to distinguish it from related concepts such as equity, fairness and equality.  
In the following sub-chapters, different theories of severity will be presented. The theories 
stress different factors in the determination of how to compute and understand severity level.  
3.2.1 The severity of illness approach 
The severity of illness approach embodies the feeling that people with severe conditions (e.g. 
facing immediate death) must be prioritized. For instance, if individual A can be taken from 
0.4 to 0.6 on a 0-1 utility interval scale, and individual B can be taken from 0.6 to 0.8, then 
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the former improvement would be valued higher than the latter, all else being equal. A more 
comprehensive example has been illustrated by Shah (2009), adapted from Nord (1993b): 
  
The arrows represent possible gains from intervention for individual A, B and C. A and B has 
the same capacity to benefit from intervention (three-level improvement in health state), but 
in the absence of treatment, A finds himself in a worse health state than B – he is more 
severely ill than B. The severity of illness approach suggests that other things being equal, the 
health gains accruing to A should be valued more highly than those accruing to B since there 
is an intrinsic value in helping the worst-off. Those who advocate allocation according to 
severity would maybe prefer to give C priority over B even though the expected health gain 
from treatment is smaller. Thus, the severity approach can involve a sacrifice of aggregate 
health in order to target the worst off (Shah, 2009) 
There is not only severity at the time of intervention that is taken into account in this 
principle, but also expected severity in future years in case of non-intervention. A problem 
with this approach may be that substantial differences in health prospects may exist not only 
because of different illnesses, but also because of age differences. Another counterintuitive 
situation arises when relatively healthy individuals must wait until their health deteriorates 
sufficiently for them to satisfy the severity of illness criterion (Nord, 2005, Shah, 2009, 
Richardson et al., 2011, Stolk et al., 2004).  
Another definition of severity is launched by Hansson et al. (1994) who states that the 
severity of disease can be defined as prognosis measured in QALYs, i.e. expected remaining 
life years adjusted for the quality of life during these years, with the existing treatment 
method. This definition is in contrast with the mentioned definition above and is more 
influenced by the time dimension and preference for younger individuals.  
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3.2.2 Fair innings 
The equity principle of fair innings reflects the feeling that everyone is entitled to some 
“normal” span of health. Anyone failing to achieve this has been cheated, whilst anyone 
getting more than this should consider any additional years a sort of bonus. Fair innings is 
characterized by being a notion of equity being outcome based. It is about lifetime experience, 
not about an individual’s state at any particular point in time. It reflects an aversion to 
inequality, and it is quantifiable and even in common parlance it has strong numerical 
connotations. Death at 35 is viewed very differently from death at 90, and age at death is the 
key variable which is most often focused on (Williams, 1997). In an allocation situation with 
scarce health care resources, priority is given to the individuals that are most far away from 
achieving their “innings”. Unlike other approaches, fair innings includes the retrospective 
aspect of health. 
3.2.3 Prospective health 
In contrast, this approach bases its severity or equity emphasizing on the expected ill health 
(including death) over the remaining lifetime if left untreated. The principle focus on caring 
for those with poor health prospects that corresponds with that people may wish to devote 
considerable resources to improve the health of seriously ill people, particularly those who are 
in risk of facing immediate death. It also incorporates a fairness concern when it contributes 
to equalize the distribution of health. Efforts and priority should be distributed initially to 
those who can expect the worst prospective health if they are left untreated. 
3.2.4 QALYs and severity 
In CUA, the focus is how much gain in QALYs an intervention cause. If QALYs are used to 
determine the severity of a condition, the decision maker needs to have knowledge about the 
originating of the values. The QALY maximization rule entails distributive neutrality, which 
means that it does not incorporate concerns for how benefits are distributed across 
individuals. A “QALY is a QALY is a QALY” under all circumstances, regardless of to 
whom they accrue and the context in which they are enjoyed. So priority is given to the 
patient group that can gain the most from treatment independent of age and discomfort. 
However, people may be willing to sacrifice aggregate health gain in order to direct resources 
towards those who are worst off in terms of the severity of their initial condition (Olsen, 
1997). Studies also show that the health maximization solution does not have a very strong 
support among people (Cuadras-Morato et al., 2001) 
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A discussed issue is whether severity and societal concerns is actually captured in the initial 
personal utility assessments of health states used in priority settings, which is used in the 
development of QALY-values. Some support that this is captured, while others argue that the 
respondents have never expressed any opinion about priority setting or society value, but a 
quantification of the disutility they would feel with different states of illness. Since the 
respondents does not have a societal perspective we might excluding this kind of fairness 
reflections. To remove this imbalance there has been proposed various approaches to establish 
equity weights to measure and integrate society’s aversion to inequality in health outcomes  
(Nord, 1999). On the other hand, it is said that the QALY maximizing rule includes two 
central equity characteristics: 
- A QALY gain has the same societal value  irrespective of who is generating it 
(independent of income, race, gender) 
- QALY maximizing is in accordance with the utilitarian theory, which means that the 
proper course of action is the one that maximizes the overall "happiness" (utility) 
Obviously this rule does not include all equity considerations, and it is demonstrated that there 
are different understandings of equity across populations (Olsen, 2006). Some societies, like 
the Norwegian, tend to emphasize egalitarianism rather than the utilitarian view (Nord, 1999). 
Egalitarianism is a philosophy that supports equality between individuals. However, by 
modifying the QALY approach one might end up with a less transparent and easily 
understood process. 
It is challenging to design health care decision-making systems that consider all stakeholders’ 
perspectives. From a health economic perspective it is of importance to have consistent 
systems, while other groups may emphasize flexibility in severity valuations. The latter is 
illustrated in a report concerning QALYs and severity of illness from The Citizen Council 
which is an advisory body of The National Institute for Health and Clinical Excellence 
(NICE) in the UK (NICE, 2008).  Here they state that they think it is of importance to take the 
severity of a disease into account when making decisions. Furthermore, they say that they 
would prefer NHS (National Health Service) to take severity “into consideration” alongside 
the cost and clinical effectiveness evidence rather than including severity in the calculation of 
QALY. The reasons given is that including severity in the calculation of QALY will lessen 
the transparency of a committee’s decision (NICE, 2008).  
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4 METHODOLOGY AND DATA 
4.1 Study design 
This study is based on a descriptive platform where the aim is to provide information about 
how measures of medical condition’s severity can be operationalized and included in 
pharmacoeconomic analysis. Numerical data concerning medical conditions and 
pharmacoeconomic models are derived from reimbursement applications assessed by NoMA 
in the period 1.1.2009-31.12-2011. These data have been linked with life expectancy data 
from Statistics Norway (SSB) to create measures that are in touch with reality. There is in 
addition derived disease specific information to be able to present and discuss the 
measurements in an appropriate context.  
4.2 Search strategy 
 To be able to identify different measurement principles of severity it is necessary to perform 
a literature search. The method used is inspired by the handbook “Doing a systematic review” 
(freely translated) from The Norwegian Knowledge Centre for the Health Services (NOKC, 
2011). I have performed a literature search in MEDLINE and EMBASE to get a 
comprehensive search, and to assure that I capture the variety of medical journals and other 
relevant sources. The two databases are using different methods to index articles and different 
keywords are being used in the search algorithms to cover the area of interest. The important 
concept of the search is to include articles that deal with severity of illness in a health care 
prioritization context. To improve the quality of the search there has been used different 
relevant articles to check if the search algorithm captured them. 
MEDLINE EMBASE 
Searches Results Searches Results 
exp “health care economics 
and organizations”/ 
1104599 exp quality adjusted life 
year/ 
8364 
exp “Severity of Illness 
Index”/ 
138767 exp disease severity/ or 
severity of illness.mp. 
956751 
Health Priorities/ 7902 exp economic evaluation/ 178489 
1 and 2 and 3 56 1 and 2 and 3 756 
Table 1 Search strategy: literature search in MEDLINE and EMBASE 
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To include various subheadings and to ensure a broad search, most keywords had to be 
expanded (exp). After duplicate removal in EndNote, the total number of articles was 762. 
Most of these were focusing on specific diseases and the number of relevant articles that was 
included was 14. Few of these articles are precisely matching the research question, but they 
are a good basis for locating references through a snowball method. By going through the 
reference lists and looking for citing of other publications, a diverse amount of sources was 
acquired.  
4.3 Inclusion of measures 
The focus of the analysis is the severity of a condition. It is of importance to be specific so the 
measurement do not get influenced by other concerns such as equity, costs, burden of disease 
for society etc. An ideal method is a universal measure that captures the severity of a 
condition across different disease areas (making it comparable), in an unbiased, accurate and 
comprehensive manner, and in a transparent way. Different measures of severity were 
identified during the search process and the most relevant are: 
- Absolute shortfall (HDIR, 2011, Lee et al., 2010, Jia et al., 2012) 
- Before and after treatment (Hagino et al., 1998) 
- Disability-adjusted life year (DALY) (Drummond et al., 2005) 
- Disease specific measures (Revicki and Wood, 1998) 
- DRG-based severity measures (Romano and Chan, 2000) 
- Proportional shortfall (Stolk et al., 2004) 
- Value number (FHI, 2011)  
Most of the identified methods are disease specific with a usage in a clinical setting, and 
cannot be used as a generic instrument on a system level. Others are focusing on the severity 
of the pre- and post-intervention health states and the numbers of persons treated. Both the 
before/after-measure and the severity-adjusted DRGs approach are treatment-oriented, and do 
not indicate the condition’s severity. The DALY measure is developed by WHO and the 
World Bank, and is commonly used in low- and middle-income countries to assess the 
magnitude of disease, health risks, and premature death. As a measure of disease burden 
DALY could seem to be an appropriate tool in severity measurements; but it has some 
characteristics that makes in incompatible with the objectives of the Drug Reimbursement 
Scheme: 
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- Age weights that give lower weight to years of the young and the elderly   
- Cannot include impacts of side-effects and co-morbidities  
- Unable to distinguish between alternative healthcare interventions  
- Has only seven health states in addition to dead and healthy making it difficult to catch 
marginal differences 
- The weighting used in the measurements are not preference based, but based on 
valuations by a panel of healthcare workers  
- Low validity and reliability 
(Drummond et al., 2005, Fox-Rushby and Cairns, 2005) 
Another opportunity which is suggested by the Norwegian Institute of Public Health (FHI, 
2011)  and referred to as “Value number” (freely translated) is to simply subtract the QALY 
value for the condition from 1, e.g. individuals affected by condition X has a QALY value of 
0.6, and thereby have a severity value of 0.4 (1-0.6). The problem with this method is that the 
data material in the reimbursement applications only reports the QALY gain for a condition 
with an existing and with a new treatment, and do not emphasize where on the 0-1 scale the 
improvement finds place. The procedure is therefore not applicable. 
Absolute and Proportional shortfall seems to be the measures that are best transferable to the 
current topic. Both are QALY-based in estimating health utilities, they have a transparent 
calculation of severity levels, and will be introduced in the two next sections. Following by a 
section where the development of a quality-adjusted life expectancy (QALE) model is 
explained. 
4.4 Measures of the level of severity 
4.4.1 Absolute shortfall (AS) 
The procedure was first identified when doing explorative research for this thesis in a 
discussion document written by the Directorate of Health (HDIR, 2011). The procedure has 
no exact name, so for simplicity I will name it Absolute shortfall (AS). It is easy to understand 
and have a practical approach, which is illustrated in a study conducted by Lee et al. (2010), 
where the expected loss-of-QALE due to stroke are estimated. The procedure is identified in 
different variants for a variety of issues, e.g. in burden of disease studies (Muennig et al., 
2006). It assumes that the point of departure of measuring severity should be the life 
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expectancy of the general population and the HRQL of the age group that the patient belong 
to. The measure is defined as: 
(2) 
 = 	
 − 	
	  
Eq. (2) defines AS as the QALE of the general population (	
) minus the QALE of a 
particular patient group (with the existing treatment) (	
	). The size of the minuend will 
therefore be decisive in the valuation of severity level and consequently younger individuals 
will have a more favorable starting point than the elderly will. For the Norwegian population 
the QALE of a newborn is 67 (undiscounted) and represents the maximum value of the 
measure. In the following table, three age groups with three different diseases that reduce 
QALE with 40, 60 and 90 percent are being measured to illustrate the fundamental 
mechanisms of the principle: 
 
 
 
 
Table 2 Example of using AS in severity level measurement.  
The patient being the one with the largest number of lost QALE is determined to be the worst 
off in respect of severity. How old the patient is, or the average age of a patient group will 
therefore heavily affect the level of severity according to this principle, and may be an issue 
of criticism. The objections against the QALY methodology are in some cases also applicable 
to this procedure. The discrimination of the elderly is the most relevant objection being 
exemplified in Table 2 where the eldest that also has the condition with the highest proportion 
of QALE-reduction is ranked as the third most severe (Petrou and Renton, 1993). The severity 
definition stated by Hansson et al. (1994) seems to be compatible with the mechanisms and 
outcomes of AS. 
In a utilitarian approach to the CUA the aim is to prioritize the interventions that produce the 
most QALYs (Dolan et al., 2005). With AS we are also able to rank the objects after their 
score, but in this thinking, it is all about the condition and the patient group that experience 
the highest loss of QALE. A crucial difference between the two principles is that CUA is 
intervention oriented, whilst AS is condition oriented. AS’s impact on the decision material 
Patient’s age 30 50 70 
QALE for age group 50 30 10 
Disease reduces QALE with  40 % 60 % 90 % 
Absolute shortfall 20 18 9 
Ranking 1 2 3 
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would therefore lessen the effect of the QALY maximization rule, which is one of the 
essentials of including severity into health economic analysis.  
Egalitarianism advocates equal shares of the good being distributed. In this case, it can be 
understood as equal access to health care across individuals. It can also be comprehended as 
equalizing health within a population. AS has a foundation in the average individual of the 
population since QALE are being used as reference group when computing level of severity. 
The mechanisms of AS could therefore contribute to more equality. It is important to 
emphasize that this reasoning do not include the approach of strong egalitarianism, but a 
milder specific egalitarianism (Olsen, 1997, Olsen et al., 2003).  
Parts of the fair innings argument may be included as a characteristic of this principle. As 
described in chapter 3.2.2, the argument takes the view that there is some span of years that 
we consider a reasonable life. Anyone who does not achieve this span of years has been short-
changed, and should be given priority, and this may result in an age-based rationing policy 
(Rivlin, 2000). Fair innings has total life span as focus meaning the closer you are to your 
“limit”, the less priority is given. The same type of logic is recognizable for AS since it 
includes the dimension of time in the severity measure.  
 
4.4.2 Proportional shortfall (PS) 
The principle of Proportional shortfall was introduced by the Dutch researcher Elly Stolk in 
2004 (Stolk et al., 2004) and has reached a broad consensus of use in the Netherlands (van de 
Wetering et al., 2011). It is though still considered as an invention within the field of health 
economic evaluation, and is not extensively used elsewhere. The authors encourages efforts 
like the analysis conducted in this thesis, when they claim that the ultimate test of the practical 
value of the concept is to apply it to real-life situations (Stolk et al., 2004). Proportional 
shortfall (PS) is stated by the authors to be a procedure that is characterized by being an 
intermediate position between prospective health and the fair innings approach (van de 
Wetering et al., 2011). As fair innings, PS is concerned with disease-related QALE-loss. At 
the same time, in accordance with prospective health, it takes the remaining QALE 
expectation with the existing treatment into account. It assumes that measurement of severity 
in health should concentrate on the fraction of QALYs that people lose relative to their life 
expectancy, and not on the absolute number of QALYs lost or gained (van de Wetering et al., 
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2011). PS is measured on a scale from 0 (no loss of health) to 1 (maximum loss of health, or 
immediate death) using the following fraction:  
(3)  = 	 
 
=	
 !"#
 
= 1 −
"#
 
  
The numerator reflects the loss of QALE due to disease (i.e. AS), as described in the previous 
section, and the denominator reflects the remaining life expectancy, which is HRQL-adjusted 
in this analysis by using QALE. The patient with the largest proportion of lost QALE is 
thereby determined to be the one worst off in terms of severity. Thus, it wishes to equalize 
patients within their own scope of potential health, and therefore it differs from fair innings 
and prospective health in the sense that it compares individuals in relative terms to determine 
who is worse off. As a result, this principle does not discriminate elderly, but it is more 
sensitive for patients with a short life expectancy (Stolk et al., 2004, van de Wetering et al., 
2011). 
A characteristic of Proportional shortfall is that all patients who face a threat of immediate 
death will score 1, irrespective of their age, and will all receive equal weight (horizontal age 
weighting). Likewise, if a young patient with an expectation of 40 QALEs loses 20 QALY, he 
or she will get the same severity weight as an older patient with 2 QALEs loses 1 QALY: 
both patients lose 50 % of their remaining life expectancy (Stolk et al., 2004, van de Wetering 
et al., 2011).  
Table 3 illustrates the mechanisms of PS. The same age groups and the same three diseases 
that exemplified in the AS section. The ranking made my PS is the opposite of AS’ and 
illustrates the fundamental difference between the principles. 
Patient’s age 30 50 70 
QALE for age group 50 30 10 
Disease reduces QALE with  40 % 60 % 90 % 
QALE lost (AS) 20 18 9 
Proportional shortfall 40 % 60 % 90 % 
Ranking 3 2 1 
Table 3 Example of using PS in severity level measurement. 
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HRQL from 
Sweden with EQ-
5D tariffs from UK 
Life expectancy 
from Norwegian 
life table  
- Discounting  
- Time horizon 
QALE 
Figure 1 Illustration of the construction of Quality Adjusted Life Expectancy (QALE) 
4.5 Quality Adjusted Life Expectancy (QALE) 
Most of the severity approaches and measures compare the loss of health to the patient group 
or the general population. AS and PS use the general population. The reimbursement 
applications are designed for the Norwegian market, and it is reasonable to use the health of 
the general Norwegian population as a comparator. Both Lønning (p. 5) and Boorse (p. 6) 
emphasize the principle of doing comparisons with the population the patient belongs. Thus, a 
more reasonable comparison and measurement than if for example a global standard are being 
used, which is the case for the DALY measure (Drummond et al., 2005).  
Quality Adjusted Life Expectancy (QALE) is the number of years of perfect health one can 
expect to live from a certain age, and is a summary measure of mortality and Health-Related 
Quality of Life (HRQL) across different stages of life. QALE as a measure summarizes the 
overall health for the population and provides comparisons among different groups, and may 
be useful to guide policies in healthcare issues. HRQL assesses an individual’s perception of 
quality of life in relation to health or in response to the onset of a disease (Preedy and Watson, 
2010). Life expectancy is a summary of the mortality rates of age-specific groups in the 
population. Since HRQL differs across different stages of life, calculating an adjusted life 
expectancy gives a more complete measure for assessing overall health (Jia et al., 2011). 
QALE may be a contribution to making the analysis more precise than not adjusting the loss 
of health for differences in HRQL and life expectancy. The structure of QALE calculation is 
quite complicated and an attempt to illustrate the structure is done in Figure 1. 
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4.5.1 Health-Related Quality of Life (HRQL) 
There has not yet been developed HRQL-scores based on Norwegian data that is useful for 
the purpose of this thesis. It is therefore necessary to use data from close to similar 
populations. Among the Scandinavian countries, Burström and Rehnberg’s (2006) report 
concerning the HRQL of the population in Stockholm County, Sweden, seems to provide the 
most appropriate values to use in the severity calculations. To be able to quantify the HRQL 
data the commonly used EQ-5D measure was implemented in their study. EQ-5D is a 
standardized instrument for use as a measure of health outcome. It is applicable to a wide 
range of health conditions and treatments, and it provides a descriptive profile and a single 
index value for health status (EuroQol, 2012) . The EQ-5D requires respondents to classify 
their own health status according to five health dimensions (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) using three levels of severity (no 
problems, moderate problems, and severe problems) and defines 243 (3') different health 
states (Drummond et al., 2005). In general, EQ-5D is the measure used in the reimbursement 
applications to derive QALY-values.  
The measurements were included in a public health survey in 2002, and the results are based 
on data from more than 30 000 individuals aged between 18 and 84 (see appendix ii for more 
details). The survey was a cross-sectional self-administered postal questionnaire based on a 
stratified study design, where gender and area (25 municipalities and 18 districts in 
Stockholm city) were used as stratum variables (Burström and Rehnberg, 2006).  
There is no EQ-5D preference weights developed in Sweden, so the authors have used British 
preference weights (tariffs) based on the Time-trade-off (TTO) technique in the EQ-5D index 
score. Preference weights determine how much each of the five dimensions should count. In 
TTO the respondents are asked to choose between remaining in a state of ill health for a 
period of time, or being restored to perfect health but having a shorter life expectancy. Despite 
the great extensiveness of EQ-5D it is not automatically superior to other measures (Brazier 
and Ratcliffe, 2007). The implications will be addressed in the limitations chapter. 
The Swedish study sample consists of people aged 18 to 84. To get a model that incorporates 
a total life span of utility values it is necessary to supplement with values for years <18 and 
>84. A pragmatic approach was chosen to make a lifelong QALE structure: 
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- The average utility value for years 18-40 is 0.85. Children and adolescents in the age 
interval 0-18 are assumed to have a relatively high HQRL, so the value for these years 
has been set to 0.9. 
- From age interval 75-79 to 80-84, the utility value decreases with 0.05 (6.6 %). The 
same level of deterioration is applied on the age intervals 85-89 and 90-105. 
Next step in the construction of QALE is to link HRQL with life expectancy. A  life table 
from Statistics Norway (SSB) contains the necessary data and is used as source to model life 
expectancy (Table 4) (SSB, 2011).  
4.5.2 Life expectancy  
 
Table 4 Extract from life table made by Statistics Norway (SSB, 2011). Range: 0-105 years. 
 
The life table is based on the probability of dying between two age levels (number of years) 
and is indicated with the symbol )* in which x stands for years. The point of departure is a 
selected cohort of 100 000 persons of both genders, in which survivors at age x is expressed 
by +*: 
(4) +* = +*,-(1 − )*,-) 
In which (1 − )*,-) is the probability that a person aged x-1 will be alive one year later. The 
number of deceased persons by their exact age x to x+1 year in the selected cohort is: 
(5) .* = +* ∙ )* 
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To calculate the life expectancy at age x we need the auxiliary aggregates contemporary 
survivors and total remaining lifetime. The contemporary survivors of age x,  
(6) * 
is the average number of persons of age x. If deaths are assumed to fall evenly throughout the 
year, contemporary survivors are: 
(7) * =	1 21 (+* + +*3-) 
Total remaining lifetime at age x is the number of years 4567895:;:<	=>:?@?5: x-year-
olds in the cohort have to live: 
(8) A* = * + *3-+. . . +C 
Which D is equal to the highest age (105 years). Expectation of life at age x is equal to the 
total of remaining years of life at age x, divided by the number of survivors at age x. 
(9) @E7	7F974;64<	 = 7*G = HIJI   
Using the described formula to calculate life expectancy for a 50-year-old male would be to 
divide the number of remaining life years by the remaining individuals in the cohort: 
K	L'M	NLO
L'	LLK
= 30.77   
4.4.3 Implementing QALE 
Outcome measures over the full cycle of care for a medical condition should account for both 
survival and HRQL in estimating QALE. QALYs are primarily used to adjust someone’s life 
expectancy based on the levels of HRQL they are predicted to experience throughout their 
lifetime, or part of it. The number of QALYs lived in one year is simply: 
(10) 	
=	+@?7.	@6	567	<7;: = 1 ∗ ST		U@ℎ	 ≤ 1; 
From this descends that someone’s QALE at age a can be defined as: 
(11) 	
 = ∑ ST	3Y  
Where L is the residual life expectancy of the individual at age a, and t represents individual 
years within that life expectancy range  
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When implementing QALE in the severity measurement it is of importance to use the same 
approach as the developer of the pharmacoeconomic model included in their analyses. The 
most decisive components are the health measurement tool (e.g. EQ-5D), time horizon of the 
model and the discount rate. Attention is given to these concepts throughout the chapter. 
Incorporating discounting represents a value judgment on preference for current to future 
consumption (Egan, 2002). A higher discount rate means less weight to future benefits and 
NoMA recommends a 4 % annually discount rate for both costs and health effects. 
The following chart is based upon the different described components in order to clarify the 
relationships in the above sections. The y-axis need some interpretation to give sense: The life 
expectancy values are measured on a scale from 0-1 and communicate the probability of 
becoming one year older for a person being 0 years in 2010 (SSB, 2011). This means for 
example that if this person lives until he is 20 years old, it is a probability of 99.53 % that the 
person will become 21 and so on. HRQL is the average HRQL for a Swedish population on a 
scale from 0-1.QALE is life expectancy HRQL-adjusted. Since life expectancy is changing 
over time and varies for different age classes, the QALE trend line are interpreted as the 
quality adjusted life expectancy for a newborn in 2010. The difference between QALE and 
life expectancy reflects the HRQL people place on living with morbidity versus living that 
time in perfect health. When discounting QALE we can see that the graph changes shape 
communicating the “time preference” of valuing future health benefits at a lower rate. 
 
Figure 2 Illustration of the relationship between HRQL, life expectancy and QALE, and the effect of discounting 
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4.6 Data sources and limitations 
Data are obtained from drug reimbursement applications that are downloaded from NoMAs 
database archive. The content of the dossier depends on the objection of the application and 
the following inclusion criteria are used for the analysis: 
- Cost utility analysis (CUA) 
- Data about severity are expressed through QALYs  
- Information about the models’ time horizons and starting age or median age for the 
patient population is accessible  
To get a manageable volume of the data only applications received and assessed by NoMA 
during the time period 1.1.2009-31.12.2011 are included in the analysis. Table 5 illustrates the 
inclusion process communicating the number of applications left in the inclusion in the third 
column. During this period, 152 reimbursement applications were received by NoMA and of 
this, 70 were characterized as “long applications”, which means it is a comprehensive dossier 
containing a CUA. The applicant withdrew three of these and one was rejected by NoMA. 
The 25 applications that were marked as being under assessment by NoMA were excluded. 
Applications that have been rejected by NoMA by other reasons than low data quality are 
included in the analysis. 
(1) Total applications received in period 2009-2011 153 
(2) Total of long applications (CUA) 70 
(3) Excluding applications drawn back/rejected 66 
(4) Excluding applications still being assessed   41 
(5) Excluding applications that didn’t fulfill inclusion criteria 2 and 3 21 
(6) Applications included in analysis 20 
Table 5 Inclusion process of reimbursement applications 
The majority of the long applications that NoMA assesses are cost minimum analysis (CMA) 
that does not include a pharmacoeconomic model with utility values. The number of relevant 
applications consequently reduced to 20, which all used EQ-5D scores to derive QALY 
values. This is positive for the validity of the analysis since the same instrument is used in 
development the HRQL data used in QALE.  
The export of valid data is an intricate and time-consuming task assessing a number of 
sources to reduce the risk of e.g. using incorrect utility values or wrong median age of the 
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patient population. The time spent on each case varied from one hour to three days. It is a 
stepwise process where each source has to be assessed: 
1. The reimbursement report from NoMA.  
2. The dossier attached to the reimbursement application  
3. References used in the application 
4. If attached to the application, a health economic model 
5. If necessary: find data from other sources which can verify assumptions made in 1-4 
4.6.1 Time horizon and adjustments of the pharmacoeconomic models 
There are variations between the applicants regarding the time horizon they use in their 
models, often done to reduce uncertainty in their analysis. To meet this variation two methods 
are undertaken in the extraction of QALE values. For models with a lifetime perspective, 
lifelong QALE is used (e.g. osteoporosis). For other conditions, like Chronic obstructive 
pulmonary disease (COPD), where the treatment regimens only lasts for a certain time, only 
QALE within the time frame of the treatment is extracted. Figure 3 is an example that 
illustrates the severity stages of COPD. Drugs are sometimes specialized to treat specific 
stages of a disease, so to be able to catch the effects of the treatment they choose to focus the 
models perspective to a certain period. If an intervention has effect on mortality NoMA 
requires a lifetime perspective (NoMA, 2012b). This topic is discussed more in chapter 6.2.2. 
 
Figure 3 Illustration of the stages of COPD (UHS-PruittCorporation, 2012) 
 
Most of the models included in this analysis are Markov models, which are useful when a 
decision problem involves risk that is continuous over time, when the timing of events is 
important, and when important events may happen more than once. In this kind of models it is 
assumed that the patient is always in one of a finite number of discrete health states, called 
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Markov states (Sonnenberg and Beck, 1993). Time is handled as a series of discrete cycles, 
where events of interest are counted either at the beginning or at end of each cycle. In real 
life, these events can occur at any time within each cycle and are best represented as a 
continuous probability function. One of the basic assumptions underlying Markov models is 
that transitions can occur only once in each cycle. In the construction of QALE it is important 
to facilitate so transitions (mortality) can occur at any time during the cycle to counteract 
under- or overestimation. In the life table data from SSB this adjustment is done and it is not 
necessary to do further adjustments (SSB, 2011).   
4.7 Data 
The 20 reimbursement applications vary in their perspective, time horizon, discounting 
practices, data sources and underlying condition. To understand the context and the outcome 
of the severity measures, it is necessary to make a brief introduction to each of the cases. I 
will briefly explain the nature of the condition (pathophysiology), indication for treatment, 
and the modeling of the pharmacoeconomic analysis. In cases with distinct characteristics 
related to the research question, a short discussion will be undertaken. For additional 
information about the cases see appendix i and iii. 
4.7.1 Osteoporosis (Aclasta) 
Generic name: Zoledronate. 
Osteoporosis is a bone disease that leads to an increased risk of fracture. It does not only 
cause fractures, but also bedridden secondary complications that might be life threatening in 
the elderly (WHO, 2003). The model used was initially a Markov model, but was transformed 
to a “discrete event” model with the advantage that it generates a complete patient profile for 
each patient and the individual history of fracture, thus a fracture risk can be individually 
calculated. The time horizon of the model is lifetime perspective and the comparator is no 
treatment. The applicant has included the same Swedish EQ-5D values and Norwegian life 
tables as used for QALY calculation in this thesis. This will contribute to a more valid 
severity evaluation. 
4.7.2 Actinic keratosis (AK) (Aldara) 
Generic name: Imiquimod. 
AK, also known as solar keratosis, presents as scaly lesions on the skin predominantly on 
chronically sun exposed sites on fair-skinned individuals. AK is a skin-colored, or reddish 
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brown or yellowish black, ill-defined round or irregularly shaped macule or papule with a dry, 
firmly adherent scale. The lesion size is generally between 1-3 mm in diameter but can be up 
to several centimeters. AKs may exist singly in isolation or, more commonly, as multiple and 
confluent lesions. AK is considered an early stage of cancer and part of a disease continuum 
that includes squamous cell carciNoMA an invasive form of non-melaNoMA skin cancer  
(Lucas, 2006). A decision model has been structured as a decision tree. Patients are followed 
in the model for one year after initial treatment. According to the applicant a one year time 
horizon is sufficient to capture the majority of relevant costs and consequences attributable to 
AK treatment, as well as inclusion of the risk of AK recurrence. A complicating factor with 
the chosen approach is the selection of the value 1 on the 0-1 scale as the health utility for 
persons with no AK.  
 
Apparently, it seems like the AK patient population has a higher HRQL than the normal 
population, since it is modeled with a higher score (0.993). The highest score for an age group 
in QALE is 0.9, which are for nine-year olds. This makes the validity of a severity 
measurement for this condition low. A simple adjusting may be done by setting 	
 to 1 
that will result in AS: 0.007 and PS: 1 %. This is though a rough adjustment and is not 
satisfying in a real-life decision making since the uncertainty of the conclusion high. This 
application could be excluded, but is included since it serves the purpose of illustrating the 
challenges of operationalizing severity measures.  
4.7.3 Acute coronary syndromes (ACS) (Brilique) 
Generic name: Ticagrelor.  
ACS is an umbrella term for acute conditions that result from a reduction in blood flow to the 
heart muscle. These conditions range from unstable angina (UA) and non-ST-elevation 
myocardial infarction (NSTEMI) to ST-elevation MI (STEMI). In UA/NSTEMI a blood clot 
partly occludes an artery and as a result some of the heart muscle being supplied by the 
affected artery dies or is at high risk of dying. In STEMI the coronary artery is generally 
blocked off by a blood clot, and as a result much of the heart muscle being supplied by the 
affected artery starts to die (Widimsky et al., 2010). The model is a two-part construct with a 
one-year decision tree, based on data from the PLATO study, and a Markov model for long-
term extrapolation to ensure that all major clinical and resource generating events that a 
patient may experience throughout the course of their remaining life are captured. The model 
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was run for a period of forty years ensuring that costs and health outcomes were estimated 
until all patients, in principle, had died.  
4.7.4 Alzheimer dementia, moderate to severe (Ebixa) 
Generic name: Memantine.  
Alzheimer's disease (AD), the most common type of dementia, is a chronic progressive 
neurodegenerative disorder with an insidious onset. It is characterized by a progressive loss of 
cognitive and intellectual function, the ability to perform the activities of daily living as well 
as emergence of behavioral and psychological symptoms. Life expectancy of sufferers with 
AD is reduced. The median survival period from the diagnosis of Alzheimer disease is 
approximately 6 years (range 1-16 years), with about one-third of the time being spent in the 
severe stage (McKhann et al., 1984, Mohs and Cohen, 1988, Geldmacher et al., 2006). The 
model has a 5-year time horizon. This time frame is considered appropriate as AD represents 
a chronic progressive disease state with a low life-expectancy among patients with moderate 
to severe AD. Health utilities of patients were assessed with the EQ-5D, applying a time 
trade-off (TTO) algorithm. If the patients were unable to answer themselves, next to kin 
where used for response. It is known that people not affected by a particular disease rate the 
health problem more severely than people who have the disorders (Gray et al., 2011). In the 
case of AD, this phenomenon is obviously more uncertain. 
4.7.5 Acute Coronary Syndromes (ACS) (Efient) 
Generic name: Prasugrel. 
ACS is a life threatening condition and refers to any group of clinical symptoms associated 
with acute myocardial ischemia (MI) with or without infarction. Besides Stroke and 
Peripheral Arterial Disease (PAD), ACS represents a manifestation of atherosclerosis which is 
usually precipitated by acute thrombosis, induced by a ruptured or eroded atherosclerotic 
plaque, with or without concomitant vasoconstriction, causing a sudden and critical reduction 
in blood flow. Patients with ACS have a high mortality rate, primarily resulting from sudden 
deaths or the development or recurrence of acute MI (Anderson et al., 2007, Bassand et al., 
2007). There is used a Markov model consisting of 15 monthly cycles (representing the trial 
phase), a single cycle of nine months duration to round the Markov trace to two years, and 38 
annual cycles to complete a 40 year model time horizon (lifelong). There is applied an EQ-5D 
norms from the US which deviates from the Swedish norms used in the QALE calculation in 
this thesis.  
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Age US Sweden Deviation 
45-54 0.84 0.81 3.6 % 
65-74 0.78 0.795 -1.9 % 
Table 6 Comparison of EQ-5D norms 
In this case, this deviation is only a theoretical problem since the variation is minimal and 
mortality is the major driver of treatment effect. In a different setting where changes in HRQL 
were sensitive for changes, the problem could be more critical. 
4.7.6 Hormone-dependent metastatic prostate cancer (Firmagon) 
Generic name: Degarelix. 
Prostate cancer is a form of cancer that develops in the prostate, a gland in the male 
reproductive system. The cancer cells may metastasize from the prostate to other parts of the 
body, particularly lymph nodes and the bones. Symptoms may be pain, difficulty in urinating, 
problems during sexual intercourse, or erectile dysfunction. Approximately 75 % of patients 
with untreated localized prostate cancer will develop locally progressive disease within 10 
years, and 65 % of these will die from cancer. Half of patients with untreated metastatic 
disease will die within three years (Albertsen et al., 1998). With early detection, treatment can 
be effective. The model’s time-horizon covers period from initiation of hormone therapy to 
patient death.  
4.7.7 Chronic myelogenous leukemia (CML) (Glivec) 
Generic name: Imatinib. 
CML is a rare, cancer of the white blood cells. It is a form of leukemia characterized by the 
increased and unregulated growth of predominantly myeloid cells in the bone marrow and the 
accumulation of these cells in the blood (Faderl et al., 1999). The horizon of the Markov 
model is lifetime (240 cycles or 60 years) and is expected to capture all relevant costs and 
effects resulting from the treatment.  
4.7.8  Gastrointestinal Stromal Tumors (GISTs) (Glivec) 
Generic name: Imatinib. 
GISTs are soft tissue sarcomas that arise from primitive mesenchyme cells and are located 
primarily in the stomach (50%) and small intestine (25%). GISTs are considered rare and 
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occur in 10-20 per one million people. The indication in the application is for patients with 
inoperable and/or metastatic malign GISTs. The pharmacoeconomic Markov model has a 
lifetime perspective, according to the model to be 20 years or approximately 1040 
weeks/cycles (i.e. when almost 100 % of the patients in the model are dead). The company 
has only efficacy data for 225 weeks/cycles, that means that significant extrapolation has been 
done and will be associated with great uncertainty. Consequently the model was run with a 
horizon of 10 years (520 weeks/cycles). Since this is a mortal condition and treatment is 
characterized as life prolonging (median survival time using comparator has been 1.5-3-4 
years and Glivec treatment prolongs survival time with 5 years) the QALYs for the condition 
is compared with lifetime QALE. 
4.7.9 Non-small-cell lung cancer (NSCLC) (Iressa) 
Generic name: Gefitinib.  
Lung cancer is the most common cause of cancer related death. There is still a lack of 
effective treatments; five-year survival is around 15 percent, and 60-80 percent of patients 
will die within the first year of diagnosis. If left untreated, this growth can spread beyond the 
lung in a process called metastasis into nearby tissue and, eventually, into other parts of the 
body (Branden, 2008). The relevant patient population for treatment with Iressa is patients 
with advanced or metastatic NSCLC with positive EGFR mutation status in all lines of 
therapy. A relatively simple Markov model was developed to model disease progression and 
estimate costs and QALYs over a lifetime horizon, 6 years, with the different treatment 
strategies under investigation. 
4.7.10 Mild to moderate Ulcerative colitis (UC) (Mezavant) 
Generic name: Mesalazine. 
UC is a chronic disease of the colon, or large intestine that includes characteristic ulcers, or 
open tiny sores producing pus and mucus. The main symptom of active disease is usually 
constant diarrhea (sometimes bloody), of gradual onset. Currently, there is no medical cure 
for ulcerative colitis (TCCFA, 2011). There is used a Markov model to estimate costs and 
effects and the model has 9 health stages over a period of 5 years. The model’s time horizon is 
not further explained in the application or in the reimbursement report from NoMA.  
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4.7.11 Atrial fibrillation (Multaq) 
Generic name: Dronedarone. 
AF is the most common sustained cardiac arrhythmia (irregular heartbeat) in the western 
world and is a major cause of hospitalization, morbidity and mortality, long-term risk of 
stroke and congestive heart failure as the leading cause. AF is a complex, progressive and life-
threatening disease, with a 1 in 4 life-time risk for individuals over the age of 40 (Pai and 
Varadarajan, 2007, Go et al., 2001). The patient group is adult clinically stable patients with a 
history of, or current, non-permanent atrial fibrillation, to prevent recurrence or to lower 
ventricular rate. A state-transition model with patient-level simulation (discrete event) with a 
lifetime horizon (28 years) was used in the analysis with a start age for the population at 72.  
 
 
 
 
 
The utility weights used, are based on a transformation from utilities in a heart study to EQ-
5D values. According to the table, one should subtract 0.003 from the constant for each year 
to get an age-adjusted HRQL. This principle deviates from the regular EQ-5D procedure and 
may be a source of bias in a severity evaluation. A gender-neutral QALE (as used in this 
thesis) may increase the difference even more, and in this application, there were close to a 
50-50 distribution between genders. A comparison of the health utility value of a non-
diseased 72 year old has been done to prove how considerable this type of calculations might 
deviate from each other: 
- Determination of a healthy year as a 72 year old in the Multaq application  
o 1.061+(-0.003*72) = 0,845 
- Determination of a healthy year as a 72 year old using QALE methodology 
(HRQL*probability of death) 
o 0.77*0.98093 = 0.756 
- Difference: (0.845-0.756)/0.845 = 11  % 
- Difference if gender-neutral QALE = ((0.845+(0.067/2))-0.756)/0.8785 = 14 % 
Table 7 the approach for establishing patient’s utility values (source: (NoMA, 2012a) 
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This works as an illustration, but it is necessary to comment that the applicant might have 
used other values if they were required to measure the level of severity.  
4.7.12 Hepatocellular carciNoMA (HCC) (Nexavar) 
Generic name: Sorafenib. 
HCC is the most frequent type of liver cancer, being responsible for about 90 % of primary 
malignant liver tumors in adults. It is the fifth most common cancer worldwide and the third 
most common cause of cancer death. HCC is associated with a dire prognosis with median 
survival following diagnosis reported as less than 1 year and for advanced HCC, less than six 
months (Llovet et al., 2003). In order to account for the progressive and evolutionary nature 
of HCC the applicant has used a Markov model. Time horizon for the cost-effectiveness 
analysis is a patient's life time, with the possibility of analyzing for trial duration or up to 
patient lifetime in annual increments (e.g. 1 year, 2 years , 3 years, et c . up to 20 years ). 
After 14 years less than 1 % of patients are still alive and thus for the purposes of reporting 14 
years is considered a lifetime horizon. The application was rejected due to several identified 
factors that made the validity of the results questionable, with the extrapolation of efficacy 
data as the absolute most important. A standard deviation of 10.7 years in median patient age 
could have a significant effect in an evaluation of the level of severity. 
4.7.13 Chronic obstructive pulmonary disease (COPD) (Onbrez) 
Generic name: Indacaterol.  
Chronic obstructive pulmonary disease (COPD) is the co-occurrence of chronic bronchitis and 
emphysema, a pair of commonly co-existing diseases of the lungs in which the airways 
become narrowed, resulting in a gradual loss of lung function. The symptoms of COPD range 
from chronic cough, sputum production, and wheezing to more severe symptoms, such as 
dyspnea, poor exercise tolerance, and signs or symptoms of right-sided heart failure. COPD 
develops slowly. Symptoms often worsen over time and can limit the patient’s ability to do 
activities of daily life (nhlbi, 2012). The health economic model, a Markov cohort model, is 
based on a recognized structure. This model has an unusual 3 year time frame with 12 weeks 
cycles. The applicant defends the choice of time horizon with that a longer time horizon will 
considerably increase the uncertainty, since most of patients shift to second and third line 
treatment and thereby complicates the models patient flow. The patient group is characterized 
by having a stage 1 (mild) COPD. It is therefore necessary to value the QALE of the general 
population within the same time frame as used in the application (age 64-67) which will rate 
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the condition less severe than if a COPD patient cohort was followed throughout their 
lifetime. 
4.7.14 Osteoporosis (Prolia) 
Generic name: Denosumab. 
Osteoporosis is asymptomatic until the severity of disease manifest with the occurrence of 
fractures, particularly fractures of the spine, hip and forearm. It is characterized by low bone 
mineral density, which is a measure of bone strength. Patients having a low bone mineral 
density have a significantly increased risk of fractures (Hagen G, 2010).  Besides the negative 
impact on the quality of life of the individual, osteoporosis is also a very costly disease for 
society. The societal costs associated with the disease are also expected to increase in the 
future due to the increasing incidence of fractures, in addition to increased life expectancy 
(Gauthier et al., 2011). A significance of this condition is the high treatment costs, and a 
slightly improvement in utility results in cost-efficiency. The cycle length in the model is 6 
months and all patients are individually followed through the model from the age of treatment 
initiation to their time of death (or an age of 100 years). The patient population is females 
with mean age 71. The utility values are based on a Swedish study where the utility values for 
the general population differ from the utility values used in this thesis (Lundberg et al., 1999).  
4.7.15 Opioid-induced constipation in cancer treatment (Relistor) 
Generic name: Methylnaltrexone. 
Constipation is recognized as a condition with slow and incomplete bowel evacuation and a 
pathological increase in the digestive tract transit time. It is followed by symptoms such as a 
bloated stomach, discomfort, pain and pressure feeling, and has in general a negative 
influence on the quality of life of cancer patients. The use of opioids is a frequent cause of 
non-obstructive constipation. The relevant patient group is characterized by advances cancer 
illness receiving palliative care (Movik E, 2009). The Markov model is developed by The 
Norwegian Knowledge Centre for the Health Services and are not compatible with a regular 
assessment. The cost-effectiveness of the treatment has therefore partly been based on valid 
arguments from the applicant. There was no data on life expectancy or horizon for the model, 
but taken the severity of the pathophysiology into consideration it is assumed a lifetime 
horizon. 
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4.7.16 Relapse/refractory multiple myeloma (RRMM) (Revlimid) 
Generic name: Lenalidomide.  
Multiple myeloma, also known as plasma cell myeloma, is a fatal progressive cancer 
characterized by an excessive number of abnormal plasma cells in the bone marrow and the 
overproduction of intact monoclonal immunoglobulin. Without treatment, survival is around 6 
to 12 months after the diagnosis. The median survival time is around 3 years with 
conventional chemotherapy (patients’ ≥ 65 years) (Rajkumar and Kyle, 2005). The 
pharmacoeconomic model is a discrete event simulation (DES) that can address specific, real 
settings of care for patients with RRMM. Although Markov models are the most commonly 
used technique for pharmacoeconomic analysis today, the approach does not have the 
flexibility required to respond to the individual variations in time to response, duration of 
response, and survival that are typical among patients with RRMM. The time horizon of the 
model is lifetime without emphasizing the exact number of years.  
4.7.17 Severe pain/opioid induced constipation (Targiniq) 
Generic name: Oxycodone/Naloxone. 
This condition concerns patients with severe pain that only can be adequately managed with 
opioid analgesics, in accordance with the medically approved indication. Furthermore, the 
application for reimbursed use of Targiniq is limited to palliative care of patients within the 
final stages of life. This implies that terminally ill cancer patients with severe pain that only 
can be managed with opioid analgesics will constitute the patient population in question for 
reimbursement. The target patient population consists of terminally ill patients with limited 
life expectancy. Patients with incurable cancer require qualified treatment for alleviation of 
pain during the last months of their lives. The duration of the palliative phase for these 
patients will however vary. Base case time horizon was set to 6 months and included in a 
cost-utility model developed in Microsoft Excel. Since the time horizon of the model is 
limited to 3-12 months, discounting of costs and outcomes is not required. 
4.7.18 Multiple myeloma (MM) (Thalidomide Pharmion) 
Generic name: Thalidomide. 
MM is a fatal progressive cancer affecting bone marrow plasma cell development. It is 
estimated that MM accounts for 1 % of all malignant diseases and 10 % of all blood cancers. 
Age, gender and race significantly affect the incidence of MM. Age is the most significant 
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risk factor: the median age at diagnosis is between 63 and 70 years and only 2% of patients 
are younger than 40 (Durie, 2001). The median age in the analysis is 79 and will therefore be 
a typical example of different valuation by AS and PS. Without treatment, survival is six to 12 
months after the diagnosis. The median survival time is approximately: 
- Three years with conventional chemotherapy, in non-transplant-eligible patients aged 
65 and older 
- Five years with intensive chemotherapy combined with haematopoietic ASCT in 
transplant-eligible patients under the age of 65 (Sirohi and Powles, 2004) 
A Markov model with lifetime horizon is adopted for the analysis. 
4.7.19 Severe chronic hand eczema (CHE) (Toctino) 
Generic name: Alitretinoin.  
Hand eczema is considered chronic if it has persisted for 6 months or more in the absence of 
external causative factors. Additionally, patients may be classified as suffering from severe, 
refractory CHE if there is no disease improvement or transient improvement with potent 
corticosteroid treatment given for a span of 4 weeks, and when patient have avoided known 
allergens or irritants and used skin emollients and protective measures. CHE is the leading 
occupational disease and contributes to sick leave, compensation, early retirement and the 
domestic, social, and psychological impact of hand eczema is considerable (Fowler, 2008). 
The Markov model used in the reimbursement application follows a theoretical cohort of 1000 
severe CHE patients over a number of treatment iterations, for approximately 22 years, 
allowing for changes in health states at the end of each treatment cycle. A mapping exercise 
from DLQI (The Dermatology Life Quality Index) to EQ-5D was done based on published 
literature The application was rejected by NoMA based on the reason that the submitted data 
and analyzes provided too small and uncertain evidence on efficacy and cost-effectiveness 
compared to existing treatment.  
4.7.20 Diabetes type 2 (Victoza) 
Generic name: Liraglutide. 
Diabetes type 2 is a metabolic disorder that is characterized by high blood glucose in the 
context of insulin resistance and relative insulin deficiency. Due to its high prevalence, it is 
one of the largest health care challenges in the world. As well as having a high prevalence and 
increasing incidence, the condition is associated with significant morbidity and mortality 
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(Wild et al., 2004). The base case is for a population with BMIs reaching into the high 20s. 
The model is based on a series of inter-dependent sub-models that simulate the complications 
of diabetes (angina, myocardial infarction, congestive heart failure, stroke, peripheral vascular 
disease, diabetic retinopathy, macular edema, cataract, hypoglycemia, ketoacidosis, lactic 
acidosis, nephropathy and end-stage renal disease, neuropathy, foot ulcer and amputation, and 
non-specific mortality). Each sub-model in the pharmacoeconomic analyses has a semi-
Markov structure and uses time, state, time-in-state and diabetes type dependent probabilities 
derived from published sources. The time horizon was set to patient lifetime (40 years). 
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5 RESULTS 
AS has a positively skewed distribution with a mean value of 4.45 indicating that AS have 
relatively few high, very severe, values. PS has a bimodal distribution with two distinct peaks 
indicating that the majority of observations are divided between the minimum and maximum 
of the scale. The mean value is 0.46, which is the middle of the scale ranging from 0-1. Both 
measures have a relative high standard deviation.  
 
 
 
 
 
 
 
 
5.1 Analysis of the operationalization of severity 
The results are communicated through a detailed table (Table 8) and through a scatter plot and 
will be discussed more in the following chapter. Out of 20 cases, the Aldara case distinguishes 
with low comparable validity of the estimates (as described in 4.7.2). However, it serves a 
benefit of exemplifying the challenging assignment of accurately measuring and comparing 
the level of severity in pharmacoeconomic analysis.  
The first column of the succeeding table presents the trade name and the indication of the 
treatment. In addition, a specification of the type of treatment has been stated as an 
abbreviation (see underneath the table for explanation). Column two to six (d, a, b, c, t) 
illustrates the data that are included in the calculation of the severity values in the two last 
columns. The number in the time horizon-column (t) is the length of the model used in the 
reimbursement application, indicating either the patient age the model are run until (marked 
▪), or the time span independent of patient age. Some applicants state that they have a lifetime 
perspective, but does not inform about the specific time horizon. The QALY values in column 
Figure 4 Histogram – showing the distribution of data for the two severity measures 
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a are calculated by the pharmaceutical companies and are not necessary endorsed by NoMA. 
The table is ranked by AS. Ranking by PS is displayed in brackets in the last column. 
Product name and condition Discount 
rate 
QALYs 
established 
treatment 
QALE 
(general 
pop.) 
Median age 
/start age in 
model 
Time  
horizon 
AS PS 
 d a b* c T b-a (b-a)/b 
Targiniq - Severe pain opioid 
induced constipation (P) 
0 % 0.21 11.76 59 0.5  11.55 
(1) 
98 %  
(1) 
Iressa - Non-small-cell metastatic 
lung cancer (P) 
4 % 0.87 12.34 57 Lifetime (6)  11.47 
(2) 
93 %  
(2) 
Glivec (GIST) - Gastrointestinal 
Stromal Tumors (P) 
4 % 2.17 11.47 60 Lifetime (10)  9.30 
(3) 
81 %  
(6) 
Glivec (CML) - Chronic 
myelogenous leukemia (P) 
4 % 5.00 13.89 51 Lifetime (60)  8.89 
(4) 
64 %  
(9) 
Nexavar - Hepatocellular 
carciNoMA (P) 
2.5 % 0.69 9.22 67 Lifetime (14)  8.53 
(5) 
93 %  
(3) 
Revlimid - Relapse refractory 
multiple myeloma (P) 
4 % 2.19 10.54 63 Lifetime  8.35 
(6) 
79 %  
(7) 
Relistor - Opioid-induced 
constipation in cancer treatment 
(P) 
0 % 0.71 7.48 72 Lifetime (0.33) 6.77 
(7) 
91 %  
(4) 
Firmagon - Hormone-dependent 
metastatic prostate cancer (P) 
4 % 0.97 7.13 73 Lifetime 6.16 
(8) 
86 %  
(5) 
Victoza - Diabetes type 2 obese 
patients (RS) 
4 % 7.18 12.34 57 Lifetime (40)  5.16 
(9) 
42 % 
(11) 
Ebixa - Alzheimer dementia (RS) 3 % 1.21 4.82 80 Lifetime (5)  3.61 
(10) 
75 %  
(8) 
Thalidomide Pharmion - Multiple 
myeloma (P) 
4 % 2.29 4.99 79 Lifetime (29)  2.70 
(11) 
54 % 
(10) 
Toctino - Severe chronic hand 
eczema (RS) 
2.5 % 11.55 13.62 48 22 2.08 
(12) 
15 % 
(13) 
Efient - Acute Coronary 
Syndromes (SP) 
4 % 9.74 11.16 61 Lifetime (40)  1.42 
(13) 
13 % 
(14) 
Aclasta - Osteoporosis (SP) 4 % 6.17 7.13 73 Lifetime 0.96 
(14) 
13 % 
(15) 
Multaq - Atrial fibrillation (SP) 4 % 6.54 7.48 72 Lifetime (28)  0.93 
(15) 
13 % 
(16) 
Onbrez - Chronic obstructive 
pulmonary disease (COPD) (RS) 
4 % 2.14 2.96 64 3 0.82 
(16) 
28 % 
(12) 
Mezavant - Ulcerative colitis (IR) 3 % 3.44 3.85 43 5 0.41 
(17) 
11 % 
(17) 
Brilique - Acute coronary 
syndromes (SP) 
3 % 9.68 9.97 67 Lifetime (40)  0.28 
(18) 
3 %  
(18) 
Prolia - Osteoporosis (SP) 4 % 8.05 7.57 71 Lifetime (100) ▪ -0.20 
(19) 
-3 %  
(19) 
Aldara - Actinic keratosis (SP) 0 % 0.99 0.79 69 1 -0.20 
(20) 
-25 % 
(20) 
Table 8 Conditions sorted after Absolute shortfall (AS). * = QALE is discounted at the same rate as used in the 
pharmacoeconomic models developed by the applicant, reported in column d, and the procedure involves d,c and t.  IR = 
induction of remission; P = palliative treatment; RS = relieving of symptoms and/or maintenance treatment; SP = secondary 
prevention. See the appendix for a more comprehensive table. ▪ = Model is run until patient age is 100. 
 
The disease areas that are being rated as most severe is clear when studying the results of AS. 
Cancer conditions of various types hold the eight first rows. Six out of these have a median 
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age lower than 70 being a contributor to the discrepancy between AS and PS in the ranking of 
the upper part of the table. Both the table and the chart on the next page illustrate the 
concurrence and variation between the methods. To get consistent values QALE has been 
discounted at the same rate as used for QALYs in the reimbursement applications. This is less 
time-consuming than modifying the complicated models used in the reports (not all are 
available), which also could become a source of error if not done in collaboration with the 
developer. Not discounting both components (columns named a and b) at the same rate would 
lead to inconsistencies and impossible comparisons and conclusions. The differing cases of 
Targiniq, Nexavar and Relistor have a lower or no discount rate at all, because the conditions 
are associated with a near-term death. To get a more correct severity level the QALE 
component of the severity calculation has been discounted with 4 %. We can do this since  
QALE is so low and would probably not be noticeable reduced by discounting.  
A feature of the illustrations is how age influences the level of severity computed with AS. 
Patient groups with a low median age will consequently be rated more severe with AS. PS 
will on the other hand rate the conditions more severe if the expected lifetime with disease is 
short.  
   
Figure 5 Scatter plot illustrating the distribution of conditions between the two measures. IR = induction of remission; P = 
palliative treatment; RS = relieving of symptoms and/or maintenance treatment; SP = secondary prevention 
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5.2 Ranking of conditions 
In Table 8 there are differences between the AS and PS measures if the conditions are ranked 
by their severity. The differences and possible patterns will be discussed in the following 
chapter. There was conducted a nonparametric statistical measurement of AS and PS to 
investigate the strength and direction that exist between the two methods. Spearman’s rank 
order correlation coefficient that is defined as the Pearson correlation coefficient between the 
ranked variables was chosen since the data do not have a normal distribution. The determined 
relationship between the two severity measurements of 20 conditions was a strong, positive 
correlation, which was statistically significant at a 0.01 level (rs(18) = .933, P = .000).  
 
Figure 6 Matrix of a measure of statistical dependence between AS and PS 
 
The statistical measurement indicates that the two methods have corresponding rankings of 
conditions, but it does not provide information of a more comprehensive character. 
Interpreted, this means that the ranking differences are minor between the measures, 
exemplified by the measures having close to the same conditions on the upper and lower part 
of the ranked table.  
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6 DISCUSSION 
6.1 Study objectives 
In general, the analysis in this thesis intends to shed light on the issue of valuing severity in 
pharmacoeconomic evaluations used to assess whether or not drugs should be granted general 
reimbursement in Norway. The composition of this chapter is designed to explain findings in 
a manner that makes it useful as input in the ongoing severity discussion in Norway.  
The objective of the thesis is divided into two areas of interest: operationalization and 
implications. In this regard, two methods for measuring the level of severity were chosen and 
constructed to evaluate the severity level of conditions assessed by NoMA in the period 2009-
2011 for inclusion or not in the Norwegian drug reimbursement scheme. These two measures 
were also recommended to be used in the proposed pharmacoeconomic guidelines for the 
drug reimbursement scheme, but were withdrawn in the final edition due to uncertainty 
around the impacts.  
To my knowledge, this type of empirical approach has never been conducted in Norway and 
similar research design is not identified through the search strategy. Therefore an explorative 
and descriptive research design is applicable. In this chapter, the relationship between 
Norwegian policy on severity and the outcomes of the measures are discussed. The 
shortcomings of the methodologies and the challenges concerning the data material are also 
central.  
6.2 Operationalization of severity level 
6.2.1 Consistency challenges when deriving QALYs and QALE 
There are some fundamental consistency challenges in the methodology used to derive QALY 
and QALE, and therefore affects the results of AS and PS. Different sources for the two 
numbers used in the severity measures (	
 and 	
) could establish biases in the 
analysis. Most pharmacoeconomic analysis is developed abroad, and is modified to the 
Norwegian context by the pharmaceutical companies. I would like to highlight the four most 
occurred challenges which could cause bias: 
1. QALYs are computed with different methods and tools in the cases 
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- In this thesis, Swedish EQ-5D values and Norwegian life expectancy are 
important components of the analysis. Only the Aclasta case (Osteoporosis) 
has used the same data.  
2. Diverse sources of acquiring utility values 
- For some conditions, the researchers had interviewed patients with first-hand 
experience, while others used the members of the public as respondents. A 
number of empirical studies have indicated that the patients themselves tend to 
place higher values on dysfunctional health states than the members of the 
general population who do not have similar experience (Brazier and Ratcliffe, 
2007). Other applicants have used the mapping solution that enables health 
state utility values to be predicted for use in CUA when no preference-based 
measure has been included in the study (Brazier et al., 2010).  
3. A healthy individual in the applicants analysis has a higher utility value than a healthy 
individual in the Swedish HRQL scores used in QALE 
- In the Aldara case a healthy individual has the utility value of 1 and the loss of 
health if diseased by AK is only 0.007, and as a consequence this patient group 
is reported to be more healthy than the general population. 
4. 	
 is based on the general population, while the QALY values in the analysis is 
based on subgroups 
- Demographic differences between populations may affect both the HRQL and 
life expectancy 
- Some conditions are gender specific (e.g. prostate cancer for men). Females 
have a higher life expectancy, but males have a slightly higher HRQL in the 
data used in this analysis. Since 	
 is gender-neutral this could cause 
under- or overestimation of the level of severity. 
- The case of Prolia is affected by this effect and addition to 1. and 3., resulting 
in a lower value for 	
 than for the patient population. 	
 are 
only females and the utility values are from a different Swedish study than the 
one used in this thesis.  
The variation explained in the four indents are common themes in the data material used in 
the analysis. To get more reliable severity measurements harmonization of data has to be 
addressed to the developers of pharmacoeconomic models.  
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6.2.2 Applications focusing on particular age groups or stages of a 
condition 
Sometimes the pharmaceutical companies only apply for reimbursement for certain age 
groups or NoMA restricts the indication of the product for only some patient groups. The 
reason is often that treatment regimens consist of different drugs. Another reason is that there 
sometimes is only documented effectiveness and/or cost-effectiveness for parts of the 
population (subpopulations). There is common that diseases have different stages and that 
drugs are indicated to only be used in parts of a treatment. The models are therefore designed 
to include only parts of the patient population. The severity ranking of COPD (Onbrez) is a 
significant case; it is ranked as number 12 in PS and 16 in AS of the 20 cases included in the 
analysis. The applicant has limited the treatment period for only the first stage of the disease 
which affects the severity measurement. The result of a severity measurement of that kind of 
data (not having a lifetime horizon) could mislead to a under- or overestimation of a disease 
severity if not interpreted carefully. These kind of tailored applications complicate the 
severity measurements since it leaves out decisive information about the overall severity of a 
condition. Since the nature of AS includes the time aspect it fails to precisely determine the 
severity. PS is not that strongly affected, but still fails to give a total impression of the 
condition due to the data material. This kind of focusing is often done in reimbursement 
applications, and for both the applicant and NoMA, it is of importance to be specific in the 
measurement of utilities and time horizon to get valid CUAs and measurements of severity. In 
relation to the curve in Figure 3 (p. 22), this makes it more challenging to understand the 
consequences and the severity of a disease. A study conducted by Spencer et al. (2005) 
indicates that the QALY value for COPD patients given placebo with a median age 63.5 (SD 
8.48) was 4.08 (d = 0.05) which results in the following severity measures: 
- Absolute shortfall: 5.84, would have been ranked as number 9 out of 21 
- Proportional shortfall: 59 %, would have been ranked as number 11 out of 21 
The discrepancy between these findings and the case of Onbrez supports an argument of 
including lifetime perspective in evaluations of severity. This could be a request highlighted 
from NoMA to applicants when developing economic analyses and dossiers for 
reimbursement assessment. 
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6.2.3 Patient populations with a high standard deviation in age 
In conditions where the patient group has a high standard deviation in median age it could be 
misleading to use the two methods discussed in this thesis. The case of CML (Glivec) is an 
example where the patient populations median age is 51 years ranging from 18-70 years old 
with 22 % of the patients being older than 60. Since the median age of the patient group is of 
importance in the calculation of AS and PS, a high standard deviation would cause 
uncertainty in the analysis. The population used in the application is most likely 
representative for the Norwegian context, but a change in the median age would have 
noticeable effects on the severity measurement. What makes this case especially interesting is 
the effectiveness of the drug applied for. Glivec is the only (close to) revolutionary innovation 
in the study sample (see Table 16 in appendix) with a QALY gain close to five compared to 
established treatment, according to the applicant. This might get attention from patients, 
politicians, media and other stakeholders; and having good documentation of both cost-
effectiveness and severity would be vital to give reasons for a decision made. For conditions 
that affect people in all age groups it might be an idea to categorize the patient population in 
age sub-groups to get a more accurate severity determination. This is especially relevant when 
using AS where loss of life years is a potent element in the calculation.  
6.2.4 Discounting of the level of severity  
When deriving QALY values from the different cases it was chosen to use the same discount 
rate as used by the applicant to counteract biases. In AS, conditions will be valued more 
severe when using a lower discount rate. This leads to a discrimination of applications where 
using a higher discount rate, since the diminishing effect on 	
 and 	
	 is lower. 
As an action to neutralize this discrimination an attempt to modify the discounting of the 
established treatment with the discount rate required by NoMA (from 2.5 % to 4 %). This 
proved that there is not straightforward to do this by first doing a reversed discounting from 
2.5 % to zero and then discount with the 4 % rate as recommended by NoMA. The reason is 
that the discounted QALY value is a sum of calculations within the Markov model, and when 
simply reversing it we end up with a misleading conclusion. 
Another issue about discounting is whether it should be done at all when valuing severity. 
Although discounting costs and effects at different rates can lead to inconsistencies in 
reasoning and impossible conclusions (Drummond et al., 2005), the opportunity cost 
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argument for discounting health gains is hard to understand transferred to the issue of level of 
severity even if it is basically two sides of the same coin. Theoretical explanations of time 
preference and discounting is based upon diminishing marginal utility of income, risk 
aversion and shortsightedness (Richardson, 1999). There is no conformity about discounting 
of health benefits (Claxton et al., 2011, Gravelle et al., 2007). Nord (2011) recently published 
a paper where he states that the sensible argument for equal discounting of costs and benefits 
rooted in microeconomic theory, is not supported by empirical observations of individual’s 
time preferences for health. It is difficult to understand that people will devaluate future 
severity with the same perception as they devaluate future consumption when having in mind 
the characteristics of severity defined by the Lønning Commission: loss of functionality, pain, 
and discomfort (NOU, 1997). A reasonable and pragmatic approach could be to use only 
crude severity values (i.e. no discounting) of either QALE or loss of QALE, in contexts where 
severity is not incorporated in trade-off models. In other circumstances where cost and effects 
are discounted it sounds more reasonable to also discount severity to counter inconsistencies 
in reasoning.   
6.3 Implications of the severity measures 
6.3.1 The valuation of severity by the public  
Is it right to bypass the measurement of individual utility and interpret QALYs as measures of 
social valuation in themselves? When the QALY valuations are generated (e.g. by EQ-5D 
with TTO) the individuals are asked to value health states for themselves. However, when 
these data are used in decision making with a societal perspective a discrepancy occurs since 
the respondents are asked for a personal valuation, not imagining a resource allocation context 
(Nord, 1994).  A person trade-off (PTO) technique would be more precise to measure a 
societal value of a condition. PTO consists in asking people how many outcomes of one kind 
they consider equivalent in social value to X outcomes of another kind, e.g. the number of 
chronically ill people cured which is equivalent to saving 10 lives (Nord, 1995, Pinto Prades, 
1997). In reality, there are lots of methods to establish utility values for CUA, and even for 
EQ-5D values, which is reflected in the included cases. It is necessary to be pragmatic in the 
world of applied health economics, and to be able to gather adequate HRQL data at all, it 
seems like it is inevitable to use individual valuation also as a societal preference. Attempts 
has though been done to transform individual utility values to societal, see Nord (1999). This 
issue is relevant in the severity discussion because the derived QALY valuations are used in 
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both of the severity measures in the analysis, which area of application are at a population 
level. Another issue regarding quantifying of severity is the quantitative relationship between 
the conditions. Assume that both AS and PS are on a ratio scale. Then we can incorporate that 
they have properties such as having equidistant points between each of the scale elements, 
which means that for example multiple myeloma (PS=61) is twice as severe as COPD 
(PS=28). The same principle would be valid for AS (e.g. AS of 10 is twice as severe as 5). In 
theory, this sounds like a pragmatic approach, but it probably challenges how the public 
understands the severity of different conditions, and it also challenges whether or not it is a 
justification for this interpretation.  
6.3.2 Preventive treatments 
An interesting finding in the inclusion process was the very low level of measured severity of 
conditions where a vaccine was the treatment evaluated. None of these was included because 
of shortcomings of the undertaken analysis. Primary preventive actions, such as mass-
vaccination against HPV (all 12 year old girls), are usually offered to big populations, but 
because few girls actually develop cervical cancer, the QALY gain per vaccinated individual 
is quite small. This being the case, the QALY gain for the girls without treatment who would 
have otherwise been diseased has to be divided by all the individuals in the cohort. Both AS 
and PS are measuring the condition of the risk group or treated individuals and not the 
condition of the diseased. The result might be understood as counterintuitive since most 
people would characterize cervical cancer as a severe condition. Hence, this will in itself 
mean that primary preventive actions will be downgraded if AS or PS are used as measures of 
severity level. Secondary prevention (methods to diagnose and treat extant disease in early 
stages before it causes significant morbidity (NLM, 2011)) such as prophylaxis for 
cardiovascular disease (Brilique) and osteoporosis (Prolia) seems to be characterized by the 
same pattern, though not so extreme, since these patients already has an indication of 
increased risk of disease. As described on page 38, the Prolia-case is affected by more than 
one factor creating biases on the severity of the condition. When the condition is treated with 
a secondary preventive action, the result is a negative severity value. The difference is 
illustrated in Figure 7 where the conditions severity is measured at state 1) for primary 
preventive actions, and in state 2) for secondary preventive actions.  
 
 
1) Healthy 2) Indication  3) Diseased  4) Dead 
Figure 7 Simplified model of the relationship between disease states 
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The point of departure in time or disease states is therefore one of the key factors when 
determining if a condition is characterized as severe or not. All the included cases in this 
analysis have state 2) or 3) as starting point in their respective pharmacoeconomic models, 
while in the case of mass-HPV-vaccination of 12-year-old girls; the target population will be 
in state 1.  
 
Osteoporosis is represented with two cases in the analysis (Prolia and Aclasta) and the main 
purpose of both is to prevent fractures and could therefore be categorized as a secondary 
preventive action, since the patient population is indicated as a risk group. Rank wise AS 
values the conditions slightly more severe than the PS. This is in accordance with the severity 
definition by the Lønning Commission where prevention is not emphasized (NOU, 1997). 
However, many believe that prevention is the key concept that can reduce medical costs at the 
same time that it improves health. Though, a systematic review of the cost-effectiveness 
literature performed by Cohen et al. (2008) indicates that 80 percent of preventive options  
add more medical costs than they save. The conditions that are treated with a secondary 
preventive action have a low severity score in this analysis and may verify the findings in the 
systematic review.  
6.3.3 Historically severe conditions 
The comparator in the reimbursement applications are the established treatment which results 
in a situation where conditions that historically were perceived as very severe, with today’s 
treatment are considered as less severe when undertaking a severity measurement with AS 
and PS. How severe a condition is would naturally change over time, since new and better 
treatments are displacing old and less efficient treatments. Consequently we get a dynamic 
measure of a condition’s severity, and ideally AS and PS would be close to zero over time. A 
new treatment with 100 % effectiveness would for instance lead to zero in severity value for a 
condition. The treatment for HIV/AIDS is an example of a condition that has had 
extraordinary improvements the last decades, and a 20-year-old HIV-positive person starting 
antiretroviral therapy today can expect to live, on average, to the age of 69 (ATCC, 2008). 
Cardiovascular diseases are a class of diseases that have had remarkable improvements the 
last 40 years (Figure 8).  
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Figure 8 Trend in mortality from ischemic heart disease for Norwegian men in the age groups 45-64 years (FHI, 2012) 
This trend is confirmed by the severity of the two applications concerning cardiovascular 
diseases: 
- Brilique: AS = 0.77, PS =  7 % 
- Efient: AS = 1.92, PS = 16 % 
Compared to the severity values of the other 18 conditions these two are ranked at the lower 
part of table. This might lead to an imbalance between what the public perceive as severe, and 
what is considered as severe in health economic evaluations. If financial or other incentives 
being linked to severity levels, it could have an impact on research and pharmaceutical 
innovations. The pharmaceutical industry, has expressed skepticism about this way of 
operationalizing severity. They claim that it would result in an unfavorable shift of where 
research and development attention is given, and it does not take into account that most 
medical innovations often are characterized by many small improvements, not revolutions. It 
might result in that developers end their efforts for making treatments when the profits are 
“good enough” and not focusing on wiping out diseases completely (GlaxoSmithKline, 2011). 
Hence, being focused on “get one’s money worth” could lead to discrepancy between health 
care decision makers and Joe Public. On the other hand, distortion emerges if using a static 
historical severity measure. Thus, patient groups that are diseased by a historical severe 
condition would be characterized with an unrealistic level of severity independent of 
improvements in mortality and quality of life. The 500 % reduction of mortality caused by 
ischemic heart disease the last 40 years would for example not be given any influence on the 
severity level. By using a dynamic severity measure, the areas with the greatest potential for 
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improvements will be emphasized and may give priority. The argument is though in conflict 
with the wording in §2 in Regulations on the prioritization of health services and the right to 
health care which states that it is the shortfall of the condition untreated that are given priority 
(MoH, 2001). The rationale of transferring that legal statement to this topic is though 
uncertain and most people would probably characterize the consequences as illogical.  
6.3.4 Implications of the severity measure procedures 
In chapter 4.4 the main features of the principles were described, and this section will do 
comparisons of how implementable AS and PS are concerning their outcomes. The 
framework in chapter 2 and 3 will also be used to include aspects of the theories and the 
policy. Most of the attention will be given to the factor that distinguish them the most: the 
dimension of time.  
AS and PS have in common that they do not have a retrospective perspective measuring 
experienced health. Other features they share are that they do not state where on the 0-1 scale 
the condition is located, and there is not possible to separate the two components of QALY 
and QALE (time and HRQL) to evaluate the ratio. To have specific information about these 
aspects are valuable for decision makers to get a good understanding of the level of severity, 
and are an argument for supplementing case papers with additional information. AS and PS 
do though include experienced life years and expected time of death in two fundamentally 
different ways: 
- AS stress the value of emphasizing young age and the number of lost life years and 
reduced HRQL 
- PS is not that influenced by young age, but is more focused on how near in time death 
will occur  
It was expected before running the analysis that AS would be sensitive to variation in the age 
of the patient group. When operationalizing the procedure it became clear that the effect of 
discounting would reduce the age discriminating mechanism. Table 9 and Figure 9 illustrate a 
condition that cause close to immediate death being measured for different age groups. The 
max point of the AS scale shrinks from 67 to 20 and narrows the scale. In the undiscounted 
AS the severity level of a newborn (age zero) is more than eleven times higher than for 80 
year olds. For the discounted version which is the used in the analysis, the same relationship 
is less than four times as severe.  
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Death at age of 0 10 20 30 40 50 60 70 80 90 100 
AS d = 0 67.17 58.42 49.64 41.37 33.12 25.33 18.12 11.52 6.07 2.72 1.37 
AS d = 0.04 21.86 21.01 19.81 18.56 16.76 14.61 11.96 8.64 5.11 2.50 1.33 
Table 9 The effect of discounting on the AS scale 
 
 
Figure 9 Variation in the range of AS. A 4 % discount rate was used in the analysis  
 
Discounting is a recurring issue which indicates that discounting is an important component 
of severity measurements, and will be crucial to have clarified this topic with applicants when 
new reimbursement processes are initiated to be able to do valid severity measurements.      
PS has a horizontal age-weighting, i.e. equal weight to all years. If running the same example 
as done in Table 9 for PS the result would be close to 100 % for every age group independent 
of discounting rate. Since the outcome of PS is a proportional number this is not surprising, 
but PS does not completely eliminate the age dimension. In the following table there are three 
age groups, 70, 80 and 90 where all patients have one QALE left, and are compared to the 
corresponding general population. This shows how the age aspect influences PS and indicates 
a much milder inequality in the valuation than AS.  
Age Z[\]^_` Z[\]^a^ AS PS 
70 1 8.65 7.65 88 % 
80 1 5.11 4.11 80 % 
90 1 2.50 1.50 60 % 
Table 10 How age influences the PS principle 
 
How the outcomes of AS and PS are in accordance with relevant policy and the public’s 
perception of severity level is a complex question. An empirical study conducted by Stolk et 
al. (2005) investigating the distributional preferences of people, indicates that the equity 
concept of fair innings correlates most with people’s equity interpretations (r=0.95). 
0
20
40
60
0 10 20 30 40 50 60 70 80 90 100A
b
so
lu
te
 s
h
o
rt
fa
ll
Age
AS d = 0 AS d = 0.04
  
48 
 
Spearman correlation was used to analyze the rank order, and a weaker correlation were found 
for proportional shortfall (r=0.82) and severity of illness (r=-0.65). This was a Dutch 
population, but studies have previously shown a high level of accordance between the Dutch 
and Norwegian population when valuing health (Nord, 1991). As described in section 3.2.2, 
fair innings is concerned with lifetime health, and both AS and PS have a prospective 
approach. The difference is that years lived will affect AS valuations, but it does not say 
anything about the quality of those years. Robberstad (2005) has illustrated the age-weights of 
the fair innings principle as shown in Figure 10 and called it egalitarian ageism, where people 
are given gradually less weight in the distribution of scarce health care resources.  
 
Figure 10 Fair innings age-weighting 
This shape has a common feature with Figure 9 and the results from the Netherlands 
indirectly points at AS being more in line with the expectation of the public what severity 
issues matter. This could be an argument of making use of AS in severity measurements.  
On the other hand, an interpretation of the Lønning Commissions report (NOU, 1997) regards 
that PS are more in line with the understanding of severity: death risk or loss of physical or 
psychological functionality, pain and discomfort. No clear indications of age or time 
considerations. The commission also talks about loss of prognosis and to see the level of 
severity in relation to the treatment opportunities which implicit indicates that there should be 
a dimension of time in the priority evaluation. It may be that the minor influence of age in PS 
is more in line with the idea of severity recommended by the commission.  
It is not possible at this point to conclude whether AS or PS is the superior measure of 
severity level. They both have their characteristics resulting in measuring two different 
aspects of severity. AS has a broader approach to the topic including factors of equity like 
egalitarianism. This does not mean that it is an inappropriate severity measure, since this 
perception of severity has considerable support among people. PS may be characterized as 
being a more pure severity measure since the influence of the age dimension is reduced. 
However, the strong element of the prospective health approach makes it vulnerable when a 
patient group has a high median age. When seeing AS and PS in a decision-making situation 
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it is clear that they can have a positive impact and contribute to achieve a more 
comprehensive understanding of a condition in reimbursement applications. While waiting for 
a clarification from the policymakers this could be an argument of utilizing them in 
combination, given that the procedures are thoroughly prepared and the users understand their 
fundamentals. The next section will present an example of how implementation of the 
severity measures may be done, and what implications that follows.  
6.4 Trade-offs 
As decision makers want to balance the different priority criteria of health care it is necessary 
to do trade-offs in a manner that considers both a transparent and consistent process. In the 
context of this analysis, it is possible to approach the challenge with doing a trade-off between 
severity and cost-effectiveness. This is exemplified in the two following tables with a 
quantification of cost-effectiveness as an incremental cost-effectiveness ratio (ICER). The 
ICER is a measure that reports the additional benefits to be gained from a new therapy (tx) 
and at what cost (Drummond et al., 2005): 
(12) bcT = deffghgijg	ei	jkk	lgmggi	*nio	*p
deffghgijg	ei	qgJq	gffgjk	(rk)	lgmggi	*nio	*p
 
The establishment of severity classes (mild to very severe) is an arbitrary choice made by me 
to make an impression of the trade-off. The ICER values are calculated by the pharmaceutical 
companies and are not necessary endorsed by NoMA. 
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Incremental cost-effectiveness ratio (ICER) (NOK/QALY) 
S
ev
erity
 (A
b
solute
 sh
o
rtfall)
 
 Cost-saving 
<0 
Very good 
0-50.000 
Good 
50 000-250 000 
Fairly 
250.000-500.000 
Poorly 
> 500.000 
Mild 
AS: < 1 
Mezavant 
Prolia 
Brilique 
 
 
Onbrez   
Moderate 
AS: 1-5 
Aclasta Efient 
Multaq 
 
Toctino Ebixa 
Thalidomide 
Pharmion 
 
Severe 
AS: 5-10 
Firmagon  Revlimid 
Victoza 
Relistor 
Glivec (CML) 
Glivec (GIST) 
Nexavar 
Very severe 
AS: > 10 
 Iressa Targiniq 
 
 
  
Table 11 Trade-off between cost-effectiveness (ICER) and the level of severity (AS). The threshold value of 500 000 is a 
hypothetical value derived from a report issued by the Norwegian Knowledge Centre for the Health Services (Wisløff T, 
2008). The table is an adapted version of an example used by the Norwegian Directorate of Health in a discussion paper 
(HDIR, 2011) .  The Aldara case is excluded from the table because of insufficient cost-effectiveness estimates 
 
 
Incremental cost-effectiveness ratio (ICER) in NOK 
Product name and condition ICER Product name and condition ICER 
Aclasta - Osteoporosis -439 886 Multaq - Atrial fibrillation 49 604 
Aldara - Actinic keratosis N/A Nexavar - Hepatocellular carciNoMA 679 515 
Brilique - Acute coronary syndromes 
18 257 
Onbrez - Chronic obstructive pulmonary 
disease (COPD) 
154 000 
Ebixia - Alzheimer dementia 315 000 Prolia – Osteoporosis -84 000 
Efient - Acute Coronary Syndromes 
23 482 
Relistor - Opioid-induced constipation in 
cancer treatment 
465 000 
Firmagon - Hormone-dependent 
metastatic prostate cancer 
-867 237 
Revlimid - Relapse refractory multiple 
myeloma 
247 078 
Glivec (CML) - Chronic myelogenous 
leukemia 
384 114 
Targiniq - Severe pain opioid induced 
constipation (P) 
23 482 
Glivec (GIST) - Gastrointestinal Stromal 
Tumors 
268 400 
Thalidomide Pharmion - Multiple 
myeloma 
256 547 
Iressa - Non-small-cell lung cancer 35 694 Toctino - Severe chronic hand eczema 136 767 
Mezavant - Ulcerative colitis -287 051 Victoza - Diabetes type 2 obese patients 249 653 
Table 12 Incremental cost-effectiveness ratio (ICER) presented in Norwegian Kroner (NOK) 
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Incremental cost-effectiveness ratio (ICER) (NOK/QALY) 
S
ev
erity
 (P
rop
o
rtio
n
al
 sh
o
rtfall)
 
 Cost-saving 
<0 
Very good 
0-50.000 
Good 
50 000-250 000 
Fairly 
250.000-500.000 
Poorly 
> 500.000 
Mild 
PS: < 25%  
Mezavant 
Aclasta-1 
Prolia 
Brilique 
Efient-1 
Multaq-1 
Toctino-1   
Moderate 
PS: 25-50% 
  
 
 
Victoza-1 
Onbrez+1 
  
Severe 
PS: 50-75% 
   Glivec (CML) 
Thalidomide 
Pharmion+1 
 
Very severe 
PS: 75-100% 
Firmagon+1 Iressa Targiniq 
Revlimid+1 
 
Glivec (GIST)+1 
Relistor+1 
Ebixa+2 
Nexavar 
 
 
Hepatocellular cancer (Nexavar) is characterized by being severe/very severe and having a 
poor cost-effectiveness. The condition of the patient group brings out the characteristics of the 
two measures; short remaining life expectancy for PS and relative high age for AS. The ICER 
in the case varies between 550-680’ depending on the modeling, and it is expressed by NoMA 
being above the limit of what is accepted and that the results are highly uncertain. The 
application was therefore rejected by NoMA. Some may argue that this violates the 
understanding of severity expressed by the Lønning Commission and the philosophy of the 
principles of prospective health and severity of illness. What if the analysis of the treatment 
efficacy was more certain; should the Willingness to Pay (WTP) be higher for this patient 
group at the expense of other less severe conditions? Nexavar is a life extending cancer drug 
and recent signals from the Director General of Health, Bjørn Inge Larsen, remarks that the 
health care authorities need to make some tough choices between the opportunity of  making 
use of expensive life extensive drugs or accommodate for a dignified end of life, making use 
of scarce health care resources for other groups (Larsen, 2012).  Both measures indicate that 
this is a very severe condition and when taking cost-effectiveness into consideration it seems 
like NoMA are in line with the suggested trade-off in the tables above.  
The condition of Alzheimer dementia (moderate to severe) which is the indication of Ebixa is 
the condition that has the greatest re-ordering when comparing the AS and PS measures, with 
a jump from moderate (AS) to very severe (PS). The condition is recognized as a disease that 
Table 13 Trade-off between cost-effectiveness (ICER) and the level of severity (PS). The transition of severity class 
from the AS measurement is marked with + (more severe) and – (less severe)  
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occurs among elderly and the reimbursement application is focused on patients >80 years old. 
This change between severity categories is therefore an example of the nature of the 
fundamental difference between the two measures. In the example made in this thesis, the 
willingness to pay is therefore remarkably higher when using PS and the opportunities for 
costly health care technology (drugs) for this patient group will be seriously affected by the 
approach being used. The danger of ignoring the difference between the measures is 
illustrated in this case, and is an argument for decision makers to think through what severity 
approach being used in resource distribution. 
Being defined as mild (PS) and moderate severe (AS) with a “good” cost-effectiveness 
(137 000 per QALY) Toctino is one of the two included drugs that has been rejected for 
general reimbursement by NoMA due to uncertain efficiency data and low cost-effectiveness. 
The certainty of the effectiveness data was criticized by NoMA and might be overestimated 
by the applicant. If we assume that the drug has an even weaker cost-effectiveness, this can be 
an indication of a scaled WTP in NoMAs practice where less severe conditions have a lower 
WTP. It may also be likely that the QALY gain (0.284) achieved by Toctino (vs. the 
comparator) would disappear if a stricter valuation was undertaken and the ICER would 
qualify for rejection.  
6.4.1 Double counting 
In the trade-off tables at page 50 and 51 we can witness that some conditions like Chronic 
myelogenous leukemia (CML) might be exposed for a type of double counting in a decision 
making process. The drug, Glivec, gains as much as 5 QALYs (see appendix iii) and would be 
eligible for a high WTP. In the study used in the reimbursement application the condition 
strikes relatively young people with a median age of 51. This qualifies for “severe” in the 
mentioned tables for both measures. Both the ICER and the severity measures are concerned 
with a lifetime perspective and will contribute to ageism:  
1. The gained life years of the intervention will contribute to a high QALY improvement. 
2. The severity measures are concerned with the established treatment and the morbidity 
and mortality of young individuals result in a considerable loss of QALE. 
a. especially presented in AS 
This means that in cases with an existing high severity because of absence of effective 
interventions, where the median age is low, and a new effective life-prolonging treatment is 
introduced; the age factor will have an overlapping effect. Many people would probably 
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characterize this as reasonable, but in a resource allocation process this can contribute to 
double counting resulting in a discrimination of other patient groups (e.g. elderly in severe 
pain with a lower potential for health improvements).  
6.5 Limitations 
When having an explorative approach, it is challenging to pinpoint variables, data sources or 
shortcomings of the methodology, since there are a small number of reference points 
available. Using QALE as done in this thesis has not been identified done before, and the 
method needs refinement to be successful in a priority situation. A specific issue is to make a 
model that has a weighted gender composition that matches the model developed by the 
applicant. Conditions that have homogeneous gender population should therefore be 
compared to a corresponding population since life expectancy differs between the genders, 
causing measurement errors. 
The data set consists of values derived from both NoMAs own reports and material submitted 
by pharmaceutical companies (see appendix iii). The values included in the analysis are not 
necessarily endorsed by NoMA (e.g. ICER values), and should be regarded thereafter. 
6.5.1 EQ-5D values used in the QALE procedure 
The EQ-5D values used in the QALE-measure may have been affected by several of reasons, 
e.g. how well the data from the survey represent Stockholm County’s adult population. 
Individuals with poor health may have been underrepresented in the postal questionnaire. 
Although the non-response rate was moderate (37 %), the authors claim that the results are 
probably overestimated since it is more problematic for people with a low HRQL to respond 
(Burström and Rehnberg, 2006). There is no separation of the genders in the QALE model 
used in this thesis. Since the males in the Swedish survey have throughout a higher HRQL 
score than the females, we have two factors contributing to the data being too optimistic on 
behalf of the population. One factor that may stabilize this bias is the higher response-rate by 
woman and when this HRQL data is matched with the gender neutral life tables it will 
counteract (maybe too much), since life expectancy for women is significantly higher. 
It is documented that EQ-5D is insensitive to some conditions and it may be caused by the 
relative few, 243, health states. Other similar instruments have defined more than millions of 
health states and could be more appropriate when measuring severity level. Another 
disadvantage of EQ-5D is the so-called “ceiling effect”. This effect is expressed because large 
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proportions of respondents indicate no problem and yet many of these respondents report 
problems on other instruments. It seems that this also result in milder problems getting higher 
mean values when using EQ-5D. The PS-histogram may be an indicator of this effect. These 
differences are likely to have an important effect on cost per QALY ratios but the 
phenomenon has not been thoroughly examined (Brazier and Ratcliffe, 2007). In the context 
of measuring severity, this may give undesirable effects causing incorrect ratings. Eight out of 
the 20 cases in the analysis have a severity value that might be characterized as moderate (PS: 
<30 % AS: <2.2) and according to the criticism above it is reasonable to believe that this is a 
category of conditions where inaccuracy is present. 
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7 CONCLUSION 
The purpose of this thesis has been to examine how severity measures can be operationalized 
in applications to the Norwegian Drug Reimbursement Scheme, and what the implications of 
the alternative measures are. The investigation was carried out with an explorative approach 
with an aim to give an empirical contribution to the debate concerning how a condition’s 
severity is approached. 
A contextual framework was presented including both institutional and theoretical 
dimensions. There is no existing policy on how severity should be determined in Norway, and 
governmental agencies such as the Norwegian Medicines Agency, are, therefore, using an 
arbitrary approach. Health and disease have been approached by a bio statistical theory where 
health is defined as normal functioning, based on the average health state of the population 
the individual belongs to (Boorse, 1977). Severity is understood as the magnitude of lost 
health. 
By doing a systematic search to identify severity measures, two QALY-oriented measures 
were included in the analysis. One is characterized as an absolute measure (AS) that considers 
both the age and time dimension in addition to physical and psychological discomfort, and 
mortality. The other is a proportional approach (PS) that assumes that measurement of 
severity in health should concentrate on the fraction of QALYs that people lose relative to 
their life expectancy (van de Wetering et al., 2011). 
Throughout the thesis, aspects concerning operationalization of the methods were addressed. 
To achieve valid and reliable measurements there has to be a communicated expectation from 
NoMA to the applicants about some central issues: 
- Harmonization of how utility values are derived 
- Use of lifetime horizon in the pharmacoeconomic model 
- Handling of subgroups and groups with a high standard deviation in age 
- Consistent discounting practices 
- Counteraction of double counting between the severity measurement and the CUA 
20 different drug reimbursement applications were assessed. A Spearman rank correlation 
indicated a strong, positive correlation between the two severity measures which was 
statistically significant at a 0.01 level (rs(18) = .933, P = .000). The measures have common 
features, such as putting a low level of severity on historical severe conditions and conditions 
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where primary and secondary preventive actions are prescribed. However, there was a 
significant variation in how the different conditions’ severity level was rated. Patient groups 
with a low median age were emphasized by AS and the opposite mechanism occurred for PS. 
The findings indicate that the measures are measuring two different aspects of severity, where 
AS is more concerned by aspects people would characterize as being thoughts of equity. This 
does not mean that the measure is inferior. Emphasizing lost life years at young age and long-
lasting disease are factors that people perceive as severe, and a Dutch study indicate that a 
close related approach  to AS (fair innings), are more in line with peoples preferences than PS 
(Stolk et al., 2005). The findings in this study therefore indicate that both severity measures 
may improve consistency in decision making, in addition to achieve a more comprehensive 
understanding of a condition. The methodology used in this thesis has not been seen used for 
the same purpose, and it would be interesting to see more research done on applying severity 
measures to real-life data in order to develop new and refine existing principles.  
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APPENDIX 
i. Assessed reimbursement applications 
 
Table 14 Overview of the assessed applications
Trade name Case #
Application 
received Company Indication Type of application Included/ excluded Conclusion Comments
Aclasta 09/06043 28.04.2009 Novartis Osteoporosis Indication expansion Included § 2 with conditions 
Aldara 09/16142 16.11.2009 Meda AS Actinic keratosis Indication expansion Included § 2 with conditions
Berinert 09/17757 07.05.2010 CSL Behring AB Hereditary angioedema New active agent Excluded §2 No severity info
Brilique 11/02350 31.01.2011 AstraZeneca AS Acute coronary syndromes New active agent Included §2
Canoderm 5% krem09/08896 01.07.2009 Aco Hud Nordic AB atopic dermatitis exemia New active agent Excluded Rejected Ref: conclusion
Cervarix 10/06086 03.03.2010 GlaxoSmithKline HPV vaccine New active agent Excluded §14-32 transferred HOD Vaccine, no severity info
Crestor 09/12940 07.10.2009 AstraZeneca AS Hypercolosterima New active agent Excluded Using LYG
Ebixa 10/10437 07.05.2010 H. Lundbeck Alzheimer dementia New active agent Included § 2 with conditions
Efient 09/03823 05.03.2009 Eli Lilly Acute Coronary Syndromes New active agent Included § 2 with conditions
EpiPen/EpiPen Jr.09/08921 01.07.2009 ALK Sverige AB Prophylactic shock, allergics New active agent Excluded § 2 with conditions CMA
Exforge HTC 09/15631 09.11.2009 Novartis Norge AS Hypertension New combination Excluded §2 No CUA
Ezetrol 09/03704 03.03.2009 MSD Norge AS Aterosclerotis New active agent Excluded § 2 with conditions No QALY weights
Firmagon
09/10247
24.07.2009 Ferring
Hormone-dependent metastatic 
prostate cancer
New active agent
Included
§ 2 with conditions
Gardasil 09/16212 18.11.2009 Sanofi Pasteur MSD AS HPV vaccine New active agent Excluded §14-32 transferred to HODNo severity info
Glivec 09/03012 18.02.2009 Novartis GIST and CML New active agent Included sendt innstilling
Grazax 09/02619 10.02.2009 ALK Abelló Rhinitis Indication expansion Excluded CMA
Iressa 09/18176 28.12.2009 AstraZeneca AS Non-small-cell lung cancer New active agent Included §14-32 transfer to HOD
Januvia 09/05261 03.04.2009 MSD diabetes T2 New active agent Excluded § 2 with conditions No QALY values
Klexane 09/00219 07.01.2009 sanofi aventis Trombosis profylaxis Excluded "short" application
Levemir 10/09779 16.04.2010 Novo Nordisk diabetes T2 Indication expansion Excluded No to § 2 Too simple analysis
Mezavant 09/05273 03.04.2009 Shire pharmaceutical contractsUlcerative colitis Ny formulering/legemiddelformIncluded
Multaq 10/11831 31.05.2010 Sanofi-aventis AS Atrial fibrilation New active agent Included
Nexavar 09/06842 14.05.2009 Bayer AB Hepatocellular carcinoma New active agent Included Rejected
Onbrez
10/05025
08.02.2010 Novartis Norge AS
Chronic obstructive pulmonary 
disease (COPD)
New active agent
Included
§ 2 kode ICPC R95, ICD J43,J44
Onglyza 09/15648 03.11.2009 AstraZeneca AS Diabetes mellitus II New active agent Excluded § 2 with conditions CMA
OsvaRen 10/12603 14.06.2010 Vingmed AS Dialyse Ny formulering/legemiddelformExcluded § 2 with conditions CMA
Pradaxa 09/06401 06.05.2009 sanofi aventis Trombosis profylaxis New active agent Excluded § 2 with conditions CMA
Prolia 10/13347 24.06.2010 GlaxoSmithKline Osteoporosis New active agent Included § 2 with conditions
Relistor
10/10640
10.05.2010 Pfizer AS
Opioid-induced constipation in 
cancer treatment
New active agent
Included
§ 2 with conditions
Renvela 10/04263 09.02.2010 Genzyme hyperphosphatemia Indication expansion Excluded §2, kun refusjon til dialysepasienter, ikke predialyse, spesialistvilkårNo CUA
Revlimid
10/04668
15.02.2010 Celgene Europe Limited
Relapse refractory multiple 
myeloma
New active agent
Included
§ 2 with conditions
Sutent 10/19410 04.10.2010 Pfizer Metastatic kidney cancer Indication expansion Excluded § 2 with conditions No CUA
Symbicort 09/04074 10.03.2009 AstraZeneca AS COPD New active agent Excluded Sent recommendation No CUA
Targiniq
09/17010
02.12.2009 Mundipharma
Severe pain opioid induced 
constipation
New combination
Included
§ 2 with conditions
Tasigna 11/04422 01.03.2011 Novartis Leukemia New active agent Excluded § 2 CMA
Thalidomide Pharmion09/04989 24.03.2009 Celgene Europe Limited Multiple myeloma New active agent Included
Toctino 09/16349 05.07.2010 Basilea Pharmaceuticals Severe chronic hand eczema New active agent Included Rejected
Tredaptive 09/09266 07.07.2009 MSD Norge AS Dyslipidemia New active agent Excluded No to § 2 Rejected model
Trobalt 11/06762 19.04.2011 GlaxoSmithKline Epilepsia New active agent Excluded § 2 CMA
Victoza 09/17136 03.12.2009 Novo nordisk Skandinavia Diabetes type 2 obiese patients New active agent Included § 2 with conditions
Votrient 10/14295 12.07.2010 GlaxoSmithKline Kidney cancer New active agent Excluded Rejected CMA
Xarelto 09/08239 15.06.2009 Bayer AB Trombosis profylaxis New active agent Excluded § 2 with conditions Insufficient CUA)
Zarzio 10/21928 22.09.2010 Sandoz Neutropenia Generika Excluded § 2 CMA ("kort/lang")
CUA = Cost utility analysis Included 19
(The Glivec application is split 
into two
CMA = Cost min analysis Excluded 24
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ii. EQ-5D utility values 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 15 Swedish EQ-5D values 
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iii. Severity calculation 
 
Table 16 Severity calculations 
R = Reimbursement report V = Appendix to application X = Assumption, missing data AS = Absolute shortfall H = Health economic model (manually run)
S = Application from company A = Study used in application N/A = Not available PS = Proportional shortfall
Total applications: 20 Discount rate 4.0 %
Product name and condition
QALY 
established 
treatment
QALY new 
treatment ∆ QALY Method
Discount 
rate Population ICER
Median age  / 
start age in 
model Time horizon QALE AS PS
Discounted 
QALE AS (4 % disc.)
PS (4 % 
disc.)
Disc. 
adjusted AS
Disc. 
adjusted PS
Iressa 0.870 0.990 0.120 EQ-5D (VAS/SG) 4.0 % UK 35 694kr           57 Lifetime (6) 19.752 18.882 96 % 12.338 11.468 93 % 11.47 93 %
Non-small-cell lung cancer R R R R S R R S
Brilique 9.681 9.8138 0.133 EQ-5D 3.0 % International 18 257kr           67 Lifetime (40) 12.947 3.266 25 % 9.965 0.28 3 %
Acute coronary syndromes R R R V R S V S
Toctino 11.548 11.832 0.284 EQ-5D (mapping) 2.5 % Northern Europe 136 767kr        48 22 17.507 5.959 34 % 13.623 2.08 15 %
Severe chronic hand eczema S S S S R S R V S
Relistor 0.706 0.794 0.088 EQ-5D 0.0 % US, Canada 465 000kr        72 Lifetime 0.33) 9.864 9.158 93 % 7.478 6.772 91 % 6.77 91 %
Opioid-induced constipation in cancer treatmentV V V V R,S A R A X
Ebixa 1.214 1.238 0.024 EQ-5D 3.0 % UK 315 000kr        80 Lifetime (5) 5.580 4.366 78 % 4.824 3.61 75 %
Alzheimer dementia R R R R A R S S
Prolia 8.048 8.067 0.019 EQ-5D 4.0 % International 283 067kr        71 Lifetime (100) 10.438 2.390 23 % 7.813 -0.23 -3 %
Osteoporosis H H H R H S R R
Revlimid 2.190 2.950 0.760 EQ-5D 4.0 % International 247 078kr        63 Lifetime 15.569 13.379 86 % 10.535 8.345 79 % 8.35 79 %
Relapse refractory multiple myeloma R R R S R S S
Onbrez 2.142 2.150 0.008 EQ-5D 4.0 % Spain 154 000kr        64 3 3.134 0.992 32 % 2.960 0.818 28 % 0.82 28 %
Chronic obstructive pulmonary disease (COPD)R R R R S R R S S
Victoza 7.180 7.400 0.220 EQ-5D 4.0 % Denmark 249 653kr        57 Lifetime (40) 19.752 12.572 64 % 12.338 5.158 42 % 5.16 42 %
Diabetes type 2 obiese patients R R R S S S R S S
Targiniq 0.213 0.220 0.007 EQ-5D (SF-36) 0.0 % Europe, Israel 217 316kr        59 0.5 18.333 18.120 99 % 11.763 11.551 98 % 11.55 98 %
Severe pain opioid induced constipation S S S S R S R S S
Aldara 0.993 0.994 0.0007 TTO 0.0 % International 991 763kr        69 1 0.794 -0.199 -25 % 0.794 -0.199 -25 % -0.20 -25 %
Actinic keratosis S S S A S S R S, U S
Firmagon 0.968 1.020 0.052 N/A 4.0 % Norway -867 237kr       73 Lifetime 9.286 8.318 90 % 7.127 6.159 86 % 6.16 86 %
Hormone-dependent metastatic prostate cancerR R R R S S R
Glivec (CML) 5.000 9.960 4.960 EQ-5D 4.0 % International 384 114kr        51 Lifetime (60) 24.114 19.114 79 % 13.887 8.887 64 % 8.89 64 %
Chronic myelogenous leukemia S S S A R R S S
Glivec (GIST) 2.170 4.020 1.850 EQ-5D 4.0 % International 268 400kr        60 Lifetime (10) 17.633 15.463 88 % 11.467 9.297 81 % 9.30 81 %
Gastrointestinal Stromal Tumors R R R A R S R A S
Efient 9.740 9.780 0.040 EQ-5D (US QALE) 4.0 % International 23 482kr           61 Lifetime (40) 16.934 7.194 42 % 11.160 1.420 13 % 1.42 13 %
Acute Coronary Syndromes R R R S S S R S S
Nexavar 0.690 1.120 0.430 EQ-5D 2.5 % International 679 515kr        67 Lifetime (14) 12.947 12.257 95 % 9.225 8.535 93 % 8.53 93 %
Hepatocellular carcinoma V V V S R S R S S
Mezavant 3.441 3.459 0.018 EQ-5D 3.0 % US -287 051kr       43 5 4.082 0.641 16 % 3.852 0.41 11 %
Ulcerative colitis R R R R R S R R S
Thalidomide Pharmion 2.290 3.170 0.880 EQ-5D 4.0 % Belgium, France 256 547kr        79 Lifetime (29) 6.081 3.791 62 % 4.986 2.696 54 % 2.70 54 %
Multiple myeloma S S S S R V R V S
Aclasta 6.166 6.201 0.035 EQ-5D 4.0 % International -439 886kr       73 Lifetime 9.286 3.120 34 % 7.127 0.961 13 % 0.96 13 %
Osteoporosis S S S S R A R S S
Multaq 6.543 6.804 0.261 EQ-5D 4.0 % US 49 604kr           72 Lifetime (28) 9.864 3.321 34 % 7.478 0.935 13 % 0.93 13 %
Atrial fibrilation V V V R R S V V V
